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INTRODUCTION
In 2008, the House Energy and Commerce Subcommittee on
Oversight and Investigations conducted a hearing on the Food and
Drug Administration's ("FDA") investigation of an external
researcher accused of fraudulently conducting clinical studies.'
Special witness Senator Charles Grassley, then Ranking Member of
the Senate Finance Committee and a reputed protector of federal
* @ 2013 Andrew C. Baird.
1. See Press Release, Office of Senator Charles Grassley, Grassley Law Recovers
Another $2.8 Billion of Taxpayer Money Otherwise Lost to Fraud (Dec. 19, 2011),
available at http://www.grassley.senate.gov/news/Article.cfm?customel-dataPagelD_1502
=38341.
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health spending programs,2 expressed serious concern over the
FDA's management of its Office of Criminal Investigations ("OCI"),
the office responsible for managing the Agency's criminal
investigations.' Specifically calling out problematic interactions
between Senate staff and OCI officials, the Senator's statements
formed the basis for a Government Accountability Office ("GAO")
investigation into the operational effectiveness of OCI's internal
procedures. Two years later, in January 2010, the GAO released its
report on the investigation, highlighting several systematic
recommendations for the OCI to implement.'
In response to congressional and GAO concerns over the OCI
issue, President Obama's FDA Commissioner, Dr. Margaret A.
Hamburg, penned a letter to Senator Grassley in March 2010
emphasizing the FDA's commitment to implementing remedial
measures.' Amongst the Commissioner's commitments was a plan to
increase the use of misdemeanor prosecutions "to hold responsible
corporate officials accountable."' This plan marked the official return
of the long-dormant responsible corporate officer doctrine ("RCO
doctrine") in the pharmaceutical and health care industries. Also
known as the Park doctrine in the pharmaceutical context,' the
Commissioner's letter only confirmed what her agency and its parent,
the Department of Health and Human Services ("HHS"), had
already begun: a regulatory offensive against pharmaceutical and
health care entities and their executives.
2. Id. Grassley's reputation for stringent government oversight stems largely from
the success of his 1986 Amendments to the False Claims Act, which have netted recoveries
over $30 billion since their passage. See id.
3. See Keteck Clinical Study Fraud: What Did Aventis Know?: Hearing Before the H.
Subcomm. on Oversight and Investigations of the Comm. on Energy and Commerce, 110th
Cong. 78 (2008) (statement of Sen. Charles E. Grassley, Member, H. Comm. on Energy
and Commerce).
4. See U.S. GOv'T ACCOUNTABILITY OFFICE, GAO-10-221, FOOD AND DRUG
ADMINISTRATION: IMPROVED MONITORING AND DEVELOPMENT OF PERFORMANCE
MEASURES NEEDED TO STRENGTHEN OVERSIGHT OF CRIMINAL AND MISCONDUCT
INVESTIGATIONS 2 (2010), http://www.gao.gov/new.items/d10221.pdf [hereinafter GAO
Report].
5. Letter from Margaret Hamburg, Comm'r, Food & Drug Admin., to Sen. Chuck
Grassley, Member, H. Comm. on Energy and Commerce (Mar. 4, 2010), http://
www.fdalawblog.net/files/fda-grassley-Itr.pdf.
6. See id. at 2.
7. The term "Park doctrine" is occasionally used because the government's use of
this prosecution doctrine was solidified in the 1975 case United States v. Park, 421 U.S. 658
(1975).
8. See Letter from Margaret Hamburg to Sen. Chuck Grassley, supra note 5. For
evidence that the Obama Administration has become more aggressive in its
pharmaceutical regulatory prosecution, see James S. Cohen & Michael W. Peregrine, The
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As the FDA, HHS, and Department of Justice ("DOJ") more
aggressively enforce a certain class of health care offenses, the Park
doctrine has reemerged as an attractive legal mechanism to help
achieve these agencies' goals of increased compliance and obedient
executives.' Originally established in 1943 in United States v.
Dotterweich0 and again in 1975 in United States v. Park," the Park
doctrine is a prosecution approach available to government
prosecutors in criminal actions against individual pharmaceutical and
health care executives for misconduct committed by their
subordinates. Based on theories of vicarious liability, responsible
corporate officership, and strict liability, the Park doctrine is notably
unique in that it can result in a personal criminal conviction for
misdemeanor offenses, even when the particular defendant neither
committed the violation nor was aware of the conduct that caused the
violation. 12 The doctrine fell out of use for nearly two decades after its
genesis in the 1970s, but has recently reemerged as a potent and, as
this Comment will argue, misplaced regulatory enforcement tool. 13
The renewed use of the Park doctrine is the main focus of this
Comment. While this new use differs from the doctrine's original
formulation in several respects, it may best be characterized by the
type of legal penalties that can now follow from a Park doctrine
conviction.' Of these penalties, the most alarming is the recently
Return of the Responsible Corporate Officer Doctrine, NAT'L L. (Mar. 14, 2011), http://
www.mwe.comlinfolpubs/NLJ_031411.pdf. For evidence that the Administration has
become more aggressive in the entire health care sector, see Letter from Attorney Gen.
Eric Holder and Sec'y Kathleen Sebelius to the Am. Hosp. Ass'n et al. (Sept. 24, 2012),
available at http://www.nytimes.com/interactive/2012/09/25/business/25medicare-doc.html.
9. Park doctrine prosecutions have thus far been used almost exclusively to enforce
provisions of the Food, Drug, and Cosmetic Act (FDCA) § 1, 21 U.S.C. § 301 (2006), but
there is nothing limiting its use only to this particular piece of legislation.
10. 320 U.S. 277 (1943).
11. 421 U.S. 658 (1975).
12. This common understanding of the doctrine is premised on the Supreme Court's
language in Dotterweich. See Dotterweich, 320 U.S. at 281 (noting that the legislation
under which the case was brought "dispenses with the conventional requirement for
criminal conduct-awareness of some wrongdoing"); Norman Abrams, Criminal Liability
of Corporate Officers for Strict Liability Offenses-A Comment on Dotterweich and Park,
28 UCLA L. REv. 463, 464 (1979) ("The most common [interpretation of Dotterweich] is
that the case established strict, vicarious liability for corporate executives.").
13. See John R. Fleder, Douglas B. Farquhar & Thomas Scarlett, FDA and the Park
Doctrine, FDA L. BLOG, at 19-26 (Oct. 10 2010), http://www.fdalawblog.net/files/fda-and-
the-park-doctrine.pdf.
14. The primary penalty of concern to health care executives is the exclusion penalty,
a sanction that prevents an individual from working for any entity that receives funding
from any federal health care program (and also penalizes any entity that employs an
excluded individual). See Social Security Act § 1128,42 U.S.C. § 1320a-7 (2006).
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approved usage of HHS's exclusion authority." Exclusion is an
administrative penalty levied by HHS against individuals who are
deemed to pose a threat to the integrity of the federal health care
programs, whereby the excluded individual is prohibited from
obtaining any reimbursement from any federal health care program,
or working for any company that receives such reimbursements.1 6 The
federal health care exclusion authority effectively functions to
prevent a convicted individual from working for or with any entity
that receives funding from a federal health program for a period of
years."
Under the authority of the Social Security Act ("SSA"), the
Secretary of HHS is responsible for excluding individuals.' The SSA
sets out the circumstances under which an individual or entity must
be excluded (mandatory exclusion) and when an individual may be
excluded (permissive exclusion)." The former applies to more serious
cases of criminal conduct as well as certain felonies; the latter applies
to a series of less serious criminal charges, including misdemeanors
relating to fraud or the delivery of controlled substances.2 0 Regardless
of how the conviction arises, either through a traditional conviction
based on direct individual mens rea or through a more attenuated
Park-type approach, an exclusion penalty effectively renders the
excluded individual incapable of continuing his or her career in the
health care field for the given sentence."
It is important to properly distinguish between the Park doctrine
and the exclusion penalty. Exclusion only comes into play once an
15. See Friedman v. Sebelius, 686 F.3d 813, 816, 820, 823 (D.C. Cir. 2012) (holding
that HHS is permitted to exclude individuals who are convicted for health care offenses
under the Park doctrine).
16. See Background Information, DEP'T HEALTH & HUMAN SERVS., OFF. OF
INSPEcTOR GEN., https://oig.hhs.gov/exclusions/background.asp (last visited Oct. 27,2012)
(outlining the various reasons an individual may be excluded).
17. See 42 U.S.C. § 1320a-7(c).
18. See id.
19. See id.
20. For example, individuals convicted of the more egregious offense of felony health
care fraud under 42 U.S.C. § 1320a-7(a)(3) are subject to mandatory exclusion with a
minimum term of five years, whereas individuals convicted of the less egregious offense of
misdemeanor health care fraud under 42 U.S.C. § 1320a-7(b)(1)(A) are potentially subject
to permissive exclusion for a minimum term of three years.
21. Peter Suber, An Open Access Mandate for the National institutes of Health, 2
OPEN MED. 39, 39 (2008), available at http://www.openmedicine.cal
article/viewarticle/213/135. Because of the size of the Medicare and Medicaid markets (not
to mention other markets driven by federal health spending), nearly every American
pharmaceutical company, regardless of size, receives some money from a federal health
program.
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individual has been convicted of an offense that is eligible for either
mandatory or permissive exclusion.2 2 The Park doctrine, on the other
hand, is one particular legal theory that lawyers at the HHS Office of
Inspector General ("OIG") may use to secure such an exclusion-
eligible conviction, but certainly not the only one.2 1 If an individual
knowingly or intentionally commits an exclusion-eligible offense, the
Park doctrine is unnecessary, but the exclusion penalty may still be
applied.2 4
This Comment focuses on the recent and increasing link between
the Park method of conviction and the accompanying exclusion
penalty and examines the implications of this combination for
corporate counsel and executive officers in the health care and
pharmaceutical industries. The types of offenses that trigger exclusion
eligibility are generally known as public welfare offenses, a class of
offenses that fits neatly into other forms of criminal offenses ("such as
those against the state, the person, property, or public morals").2
Historically, penalties for these types of offenses were "relatively
small, and conviction [did] no grave damage to an offender's
reputation." 26 However, the availability of the exclusion penalty in
the wake of a Park conviction has changed the tenor of the historical
relationship between violation and punishment. To demonstrate just
how serious the concern around Park liability has become, insurance
companies in early 2012 began offering personal insurance against
losses resulting specifically from Park doctrine convictions, even
covering losses stemming from exclusion penalties.2 7
The combination of the Park prosecution and the application of
the exclusion penalty raises legitimate fairness concerns. Combining a
Park prosecution and the exclusion penalty represents a severe
22. See 42 U.S.C. §§ 1320a-7(a)(1)-(a)(4) and §§ 1320a-7(c)(3)(G)(i)-(ii) for offenses
mandating exclusion; see also §§ 42 U.S.C. § 1320a-7(b)(1)-(b)(16) for offenses that may
result in exclusion.
23. See id. § 1320a-7(b)(15) (stating that individuals controlling a sanctioned entity
may be similarly sanctioned under the statute).
24. Exclusion can be attached to any exclusion-eligible conviction, regardless of the
prosecution theory through which that conviction occurs. See supra note 22 and
accompanying text.
25. Morissette v. United States, 342 U.S. 246, 255 (1952) (discussing the nature of
public welfare offenses).
26. Id. at 256.
27. See Anna Gaynor, Marsh, Allied Word Partner on Responsible Corporate Officer
Coverage, Bus. INS. (Feb. 9, 2012, 12:06 PM), http://www.businessinsurance.com/
article/20120209/NEWS07/120209867; see also Kathleen M. Boozang, A New Insurance
Product: Responsible Corporate Officer Doctrine Defense Insurance, HEALTH REFORM
WATCH (Mar. 8, 2012), http://www.healthreformwatch.com/2012/03/08/a-new-insurance-
product-responsible-corporate-officer-defense-insurance/.
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sanction against business leaders who, despite their best efforts, may
simply have been unaware of the particular criminal conduct
occurring at their company. But the main legal reason this new
formulation of the Park doctrine should raise concern is that HHS did
not possess the authority to exclude individuals from the health care
industry until 1977, two years after the Supreme Court considered and
narrowly approved the use of the Park doctrine and its controversial
ability to extend liability to responsible directors, officers, and
executives. 8 In debating the legality of the government's ability to
secure convictions of individuals using the doctrine, the Court was
operating in light of then-existing federal penalty and sentencing
guidelines, which did not include exclusion.29 In other words, because
the risks involved in the outcome of a Park prosecution are now so
much more severe than those that existed under the original
sentencing practices, there is no applicable Supreme Court precedent
for the current doctrinal use.
In the original Park doctrine cases, courts applied much less
severe penalties, typically fines or temporary sales injunctions of
certain products." The exclusion authority in the context of a Park
prosecution should be viewed as an entirely different circumstance
since it restricts an individual's freedom to pursue his or her choice of
employment via a quasi-strict liability prosecution approach.
The potential harm of a Park-exclusion penalty goes further.
Executive stability in today's economy often plays a role in a
corporation's market value." In a public corporation, the unexpected
removal of a leading executive harms not only the executive himself,
but also the corporation's management structure and, ultimately, the
shareholders.
28. The exclusion authority did not exist in its modern form until 1996, with the
passage of HIPAA. See H.R. REP. No. 95-3, at 1-2 (1977).
29. United States v Park, 421 U.S. 658,670-71 (1975).
30. See, e.g., id.; United States v. Dotterweich, 320 U.S. 277, 285 (1943); United States
v. Starr, 535 F.2d 512, 515-16 (9th Cir. 1976); United States v. Y. Hata & Co., 535 F.2d 508,
512 (9th Cir. 1976).
31. See Elisabeth Dedman & Stephen W-J Lin, Shareholder Wealth Effects of CEO
Departures: Evidence from the UK, 8 J. CORP. FIN. 81, 100 (2000) ("CEO departure
announcements generally induce a negative market reaction.... Regression analysis
provides further evidence of the importance investors attach to succession problems, with
a positive and significant coefficient being obtained on the replacement indicator
variable. . . . [CEO] [diepartures due to dismissal ... are consistently associated with a
negative market reaction.").
32. See, e.g., Fortinet Shares Fall on CFO Departure: Fortinet Shares Fall After CFO
Announces Plans to Move to Yahoo, YAHOO! FIN. (Sept. 26, 2012, 12:52 PM),
http://finance.yahoo.com/news/fortinet-shares-fall-cfo-departure-165226402.html (noting
that shares of Fortinet, a $3 billion corporation, dropped nearly four percentage points on
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This Comment will approach the problems with the modern Park
doctrine from historical, legal, and practical perspectives. Part I
details the history of the doctrine, focusing generally on the concepts
and theories that create its foundation and specifically the two
seminal cases that established the doctrine: the 1943 case of United
States v. Dotterweich and its progeny, United States v. Park (for which
the doctrine is named). While the Park doctrine was officially set out
in Dotterweich, it was not until the 1970s and 1980s that courts began
to decide cases that helped develop the original structure into a more
robust doctrine.
Part II addresses the doctrinal controversy surrounding the
standard by which corporate officers should be held liable under
Park. This analysis consists of a comparison between the language
used by the Supreme Court in the Dotterweich and Park cases and
legal scholarship on the criminal law notions of mens rea and strict
liability.
In light of this discussion, Part III details how the recent Park
cases depart from the former understanding of the doctrine and, more
importantly, how the arrival of the exclusion authority in this type of
prosecution represents an overreaching penalty for convicted
corporate officers in light of the "objectively possible" conduct
standard utilized in these cases.
Part IV argues that the renewed use of the Park doctrine in
conjunction with the exclusion penalty does not harmonize with the
original use of the doctrine or with the purpose of the exclusion
authority.34 Without the correct temper, the use of Park prosecutions
makes for a clumsy industry regulation tool and leaves drug
executives and their corporate counsels guessing when and if the
government will bring a Park action. Furthermore, the new Park
doctrine changes the plea calculus in response to the original
underlying government actions against a corporation. The theory
here is that, if the executive knows that he may be excluded on
account of the corporation's initial misdemeanor guilty plea, he may
seek to thwart any attempts by the corporation to plead guilty to the
the news of the CFO's departure); see also Dedman & W-J Lin, supra note 31, at 100
(outlining how CEO departure negatively affects market value).
33. See infra Parts L.A-B.
34. See Tamar Nordenberg, Inside FDA: Barring People from the Drug Industry, U.S.
FOOD & DRUG ADMIN. (Mar. 1997), http://www.fda.gov/ICECI/EnforcementActions/
FDADebarmentList/ucm139627.htm (describing exclusion authority as not a punishment,
but a method to protect the public).
2013] 955
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initial misdemeanor claims and ultimately steer more corporate
resources to their defense.
I. HISTORICAL BACKGROUND
After finding its genesis in United States v. Dotterweich in 1943
and United States v. Park in 1975, officials at the FDA and DOJ used
the original Park doctrine through the 1970s and into the 1980s.11 As
the 1980s continued, Park prosecutions became less and less frequent
as institutional trends at the DOJ made other prosecution tactics
more appealing.36 But starting in the latter part of the 2000s, the
doctrine began to resurface.
A. The Original Cases
The Park doctrine is a mixture of strict and vicarious liability.38
Its unique characteristic lies in courts' ability to punish a non-
participatory executive defendant separately and in addition to the
public welfare penalty levied on the corporate entity." The first
American case to formally recognize the validity of this type of
liability was Dotterweich.40 In Dotterweich, a pharmacy company in
New York was alleged to have violated the Federal Food, Drug, and
Cosmetic Act ("FDCA") by shipping adulterated and misbranded
drugs in interstate commerce. 41 The president of the company, Mr.
Joseph H. Dotterweich, did not participate in the shipments or even
35. See Fleder, Farquhar & Scarlett, supra note 13, at 19-26. For the history of the
Park doctrine, this account, written by men who held positions as senior lawyers at the
Department of Justice and FDA's Counsel Office during the 1970s and 1980s, is often used
as the primary first-hand account of departmental dynamics that occured during this time
period. It provides unique insight behind the opaque language of Park doctrine court
opinions. This document is a one-of-a-kind source in its ability to communicate a
perspective of the operational realities at work in these departments at the time the
modern Park doctrine was developed and tested.
36. See id. at 30.
37. See, e.g., United States v. Miller, No. 08-00023-01CR (W.D. Mo. 2009).
38. See Meyer v. Holley, 537 U.S. 280,287, 289 (2003) (referring to the RCO doctrine
as a form of "vicarious" liability); Martin Petrin, Circumscribing the "Prosecutor's Ticket
to Tag the Elite"--A Critique of the Responsible Corporate Officer Doctrine, 84 TEMP. L.
REV. 283, 300 (2011) ("[Tlhe RCO doctrine establishes a highly unfortunate species of
liability: in its most extreme form, the doctrine creates a rare type of strict and vicarious
liability in which an individual can be guilty through the acts of others with no culpable
state of mind.").
39. See, e.g., United States v. Hodges X-Ray, Inc., 759 F.2d 557, 561 (6th Cir. 1985)
(affirming the lower court's use of the RCO doctrine to hold the president and majority
shareholder of a medical equipment manufacturing company personally liable for the
company's failure to conform its devices to specific health care regulations).
40. 320 U.S. 277 (1943).
41. Id. at 278.
956 [Vol. 91
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know that they had been carried out.42 The judges at the United
States Court of Appeals for the Second Circuit did not find it
problematic that, at the trial court level, the corporation had been
acquitted of the charges for which Dotterweich was found to be
vicariously liable.4 3 After the circuit court reversed Mr. Dotterweich's
conviction, the Supreme Court again reversed, noting that the
relevant language in the FDCA "dispenses with the conventional
requirement for criminal conduct-awareness of some wrongdoing.""
Extending criminal liability to Mr. Dotterweich represented an
additional step in the Court's move toward recognizing strict liability
principles in the name of the public welfare.45 In Dotterweich, the
Court continued in this vein and employed a balancing test, pitting
the public interest against the individual's interest."
6 This sounds like
a typical procedure to determine due process,47 but here the Court
simply weighed which interest should win out over the other.
48
Specifically, the Court weighed the danger that the availability of the
misbranded drugs posed to the public against the importance of not
applying guilt to an individual that had not personally created the
42. Id. at 286 (Murphy, J., dissenting) ("There is no proof or claim that [Dotterweich]
ever knew of the introduction into commerce of the adulterated drugs in question, much
less that he actively participated in their introduction.").
43. See United States v. Buffalo Pharmacal Co., 131 F.2d 500, 502 (2d Cir. 1942), aff'd
sub nom. United States v. Dotterweich, 320 U.S. 277 (1943).
44. Dotterweich, 320 U.S. at 281.
45. See, e.g., United States v. Balint, 258 U.S. 250, 251-53 (1922) (recognizing that
Congress, in the interest of protecting the public welfare, had created certain offenses that
dispensed with the traditional common law requirement of scienter).
46. Dotterweich, 320 U.S. at 280-81 ("The prosecution to which Dotterweich was
subjected is based on a now familiar type of legislation whereby penalties serve as
effective means of regulation. Such legislation dispenses with the conventional
requirement for criminal conduct-awareness of some wrongdoing. In the interest of the
larger good it puts the burden of acting at hazard upon a person otherwise innocent but
standing in responsible relation to a public danger." (emphasis added) (citing Balint, 258
U.S. at 252)).
47. See generally Mathews v. Eldridge, 424 U.S. 319 (1976) (establishing a factor-
based test for determining procedural due process); Bd. of Regents of State Coll. v. Roth,
408 U.S. 564 (1972) (establishing the contours of procedural due process); Goldberg v.
Kelly, 397 U.S. 254 (1970) (same); Cafeteria Workers v. McElroy, 367 U.S. 886 (1961)
(same); Joint Anti-Fascist Refugee Comm. v. McGrath, 341 U.S. 123 (1951) (same); N.
Am. Cold Storage Co. v. Chicago, 211 U.S. 306 (1908) (same); Dixon v. Alabama, 294 F.2d
150 (5th Cir. 1961) (same); Bailey v. Richardson, 182 F.2d 46 (D.C. Cir. 1950) (same).
48. Dotterweich, 320 U.S. at 285 ("Balancing relative hardships, Congress has
preferred to place it upon those who have at least the opportunity of informing themselves
of the existence of conditions imposed for the protection of consumers before sharing in
illicit commerce, rather than to throw the hazard on the innocent public who are wholly
helpless.").
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danger, but still stood "in responsible relation" to it." The phrase "in
responsible relation" was the bridge that the Court relied on to
connect the misconduct to Mr. Dotterweich, in spite of the fact that
he had nothing to do with the shipments that triggered the FDCA
violation in the first place.5 0
The Court's rationale for using the "in relation to" link was
predicated on three grounds. First, the Court cited the purpose of the
FDCA legislation as the primary driver behind expanding
misdemeanor liability to Dotterweich.5 1 The familiar public welfare
rationale holds that some areas of corporate practice mix with certain
dimensions of human life that are so unguarded and fragile that strict
liability is the most effective method of preventing and discouraging
violations, even accidental ones.52 "The purposes of this legislation
thus touch phases of the lives and health of people which, in
circumstances of modern industrialism, are largely beyond self-
protection.""
In addition to the public welfare, the Court offered two other
reasons for its decision, both subtler than the obvious desire to
protect human health. The first is that this form of personal liability,
or more accurately, the threat of this form of personal liability, is a
form of industry regulation in itself.' The Court's precise language
reads:
The prosecution to which Dotterweich was subjected is based
on a now familiar type of legislation whereby penalties serve as
effective means of regulation ... . If the 1938 Act were
construed as it was [at the circuit court], the penalties of the law
could be imposed only in the rare case where the corporation is
merely an individual's alter ego. Corporations carrying on an
illicit trade would be subject only to what the House Committee
described as a "license fee for the conduct of an illegitimate
business.""
In other words, the FDCA purports to regulate food and drug
corporations by subjecting the officers of those corporations to
49. Id. at 281.
50. Id.
51. Id. at 280.
52. Id. at 281; see also United States v. Balint, 258 U.S. 250, 254 (1922) ("Congress
weighed the possible injustice of subjecting an innocent seller to a penalty against the evil
of exposing innocent purchasers to danger from the drug, and concluded that the latter
was the result preferably to be avoided.").
53. Dotterweich, 320 U.S. at 280.
54. Id. at 282-83.
55. Id. at 280-83 (emphasis added).
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personal criminal liability; otherwise, any penalty imposed on the
corporation will eventually be baked into the price of doing business.
For present purposes, the Court's view that the threat of personal
criminal liability is a form of corporate regulation serves as a segue to
the other subtle reason for finding Dotterweich guilty: the intractable
bind between the actions of the corporate entity and corporate
officers.16
The Court explained this inextricable bind clearly: "[T]he only
way in which a corporation can act is through the individuals who act
on its behalf." 7 The Court then stated, "Congress has preferred to
place [liability] upon those who have at least the opportunity of
informing themselves of the existence of conditions imposed for the
protection of consumers before sharing in illicit commerce, rather
than to throw the hazard on the innocent public who are wholly
helpless."" Yet, after announcing these general principles for finding
liability in an individual responsible corporate officer, the Court made
no attempt to help identify how a person comes to be a responsible
officer or who stands "in responsible relation to" a given FDCA
violation. 9
Thankfully, this cliffhanger is right where the 1975 case of United
States v. Park picked up.60 It was not until the decision in Park, more
than forty years after Dotterweich, that the Supreme Court began to
give more meaning to this special type of personal executive
liability.61 Dotterweich created the outline; Park colored it in.
The facts of Park are unremarkable. Mr. John Park, President of
Philadelphia's Acme Markets, Inc. ("Acme"), a national grocery
chain, was charged with violating the FDCA for allowing food, which
had traveled in interstate commerce, to become exposed to rodents in
an Acme-owned warehouse.' The company pled guilty to the
charges, accepting responsibility for allowing certain foodstuffs to be
subject to rodent infestation. Park, on the other hand, pled not
56. Id. at 281 ("[T]he only way in which a corporation can act is through the
individuals who act on its behalf.").
57. Id.
58. Id. at 285.
59. Id. ("To attempt a formula embracing the variety of conduct whereby persons
may responsibly contribute in furthering a transaction forbidden by an Act of Congress, to
wit, to send illicit goods across state lines, would be mischievous futility.").
60. 421 U.S. 658 (1975).
61. See Abrams, supra note 12, at 467 (noting the similarity between the two cases and
making the observation that the three primary interpretations of Dotterweich "suggest
that, although the time interval between the two cases was long, it was but a short step to
Park").
62. Park, 421 U.S. at 658.
9592013]
THE NEW PARK DOCTRINE
guilty.' As the president of the rather large food corporation, Park
had no personal connection with the particular circumstances
surrounding the violation and was fully unaware of the negligence
that caused it.'
Acme did have some notice about the violation, however; the
company had been warned about the problematic condition of its
warehouses in prior letters from the FDA in 1972.s Without success,
Park argued in his defense that, after hearing of the FDA letter,
[Hie . .. conferred with the vice president for legal affairs, who
informed him that the Baltimore division vice president "was
investigating the situation immediately and would be taking
corrective action and would be preparing a summary of the
corrective action to reply to the letter." Park testified that he
did not "believe there was anything [he] could have done more
constructively than what [he] found was being done."'
The Court, relying generally on the principle of the responsible
corporate officer from Dotterweich, disagreed with Park and
determined his relationship with the misconduct was such that it was
appropriate to sanction him as well as the corporation.67
According to the Park majority, the government can produce a
prima facie case by demonstrating that a corporate officer possessed
the "responsibility and authority either to prevent in the first
instance, or promptly to correct, the violation complained of, and that
he failed to do so."6" Thus, simply by virtue of his or her position in
the corporate structure, an officer can be held guilty if the
government shows he or she has some level of responsibility, even
remotely, over the operation wherein the violation occurred. Notably,
the liability can arise from either a retrospective failure or a
prospective one.69 As the Park Court laid out:
Dotterweich and the cases which have followed reveal that in
providing sanctions which reach and touch the individuals who
execute the corporate mission .. . the Act imposes not only a
positive duty to seek out and remedy violations when they
63. Id. at 661.
64. Id. at 663.
65. Id. at 662. This notice is an important aspect of this case that will be relevant to
later discussion of the doctrine's modern application.
66. Id. at 663-64 (citation omitted).
67. Id. at 676.
68. Id. at 674.
69. Id. at 672.
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occur but also, and primarily, a duty to implement measures
that will insure that violations will not occur. 0
By taking this view, the entirety of a corporate officer's role in a
company was now subject to an aggressive form of personal liability.'
However, the Court recognized one affirmative defense: "the
Act, in its criminal aspect, does not require that which is objectively
impossible."7 2 In other words, if the actions that could have prevented
the misconduct were impossible, then not having taken those actions
is an affirmative defense. This theoretically left room for those
complete and unexpected accidents, but still placed a duty on
pharmaceutical and health care executives to take extraordinary care
not only in their own actions, but in the institutional designs and
hierarchical structures that they managed.
B. Post-Park Developments
After Park made its way through the court system, use of its
underlying prosecution approach arose from time to time into the
1980s, and both procedural and tactical norms were established."
While many of these cases were settled outside of court,74 the few that
70. Id.
71. Justice Stewart's dissent, joined by Justices Marshall and Powell, deserves
momentary examination as well. The argument put forward by the three Justices stresses
that the Park majority in fact misread or overread Dotterweich. The dissent accuses the
majority of allowing a hollow jury instruction to stand and convict Park: "The
instructions ... expressed nothing more than a tautology. They told the jury:'You must find
the defendant guilty if you find that he is to be held accountable for this adulterated food.'
In other words: 'You must find the defendant guilty if you conclude that he is guilty.' "Id.
at 679 (Stewart, J., dissenting). The three dissenters believed this type of judge-jury
interaction ran counter to the deeply imbedded notions of judge and jury roles. The
dissenters pointed out that instructions such as this eliminate the need for the jury to apply
law to facts and instead merely asks them to base their determination of guilt on a sense of
social justice. Id. at 682. The group argued that basing society's most damning judgment-
criminal liability-on such volatile measures of right and wrong was offensive to the whole
notion of the court, the enterprise whose purpose is to guide juries in criminal cases. Id. at
682-83.
72. Id. at 673 (majority opinion).
73. See, e.g., United States v. Gel Spice Co., 773 F.2d 427, 435 (2d Cir. 1985); United
States v. Y. Hata & Co., 535 F.2d 508, 510-11 (9th Cir. 1976); United States v. Starr, 535
F.2d 512, 524-25 (9th Cir. 1976); United States v. Abbott Labs., 505 F.2d 565, 573-74 (4th
Cir. 1974); United States v. Shapiro, 491 F.2d 335, 336-37 (6th Cir. 1974); United States v.
General Nutrition, Inc., 638 F. Supp. 556, 563-64 (W.D.N.Y. 1986); United States v.
Torigian Labs., Inc., 577 F. Supp. 1514, 1529-31 (E.D.N.Y. 1984); United States v. New
Eng. Grocers, 488 F. Supp. 230, 232-33 (D. Mass. 1980); United States v. Treffiletti &
Sons, 496 F. Supp. 53, 55-56 (N.D.N.Y. 1980); United States v. Acri Wholesale Grocery
Co., 409 F. Supp. 529, 535 (S.D. Iowa 1976).
74. See Fleder, Farquhar & Scarlett, supra note 13, at 30 ("U.S. Attorneys often
declined to bring Park cases: Those brought typically settled with guilty pleas.").
THE NEW PARK DOCTRINE
were fully heard marked actual progress in terms of doctrinal
development. The first was United States v. Y. Hata & Co." In this
case, Minoru Hata, the president of a company that owned a food
storage warehouse, was convicted for the adulteration of rice stores
by birds that had been able to get into the facility.' Hata admitted
that he had been aware of the problem, but argued that he had made
multiple attempts to prevent the birds from getting into the
warehouse." Hata's appeal rested primarily on the claim that he did
not receive the proper jury instruction on the "objectively
impossible" defense. Although he claimed to have maintained the
standard set out in Park, the "highest standard of foresight and
vigilance," Hata argued that it was nevertheless objectively
impossible for him to have conceived of the idea of a wire cage
surrounding the facility until he actually did, at which point it was too
late." The appellate court disagreed, noting that "[o]ne maintaining
far less than the requisite 'highest standard of foresight and vigilance'
would have recognized as early as August 1971 that implementation
of a wire cage system would substantially, if not completely, prevent
access by thieving and untidy birds." 0 As was common at the time for
Park misdemeanor convictions, Hata was required to pay penalties
but did not receive any jail time."1
The other doctrinally relevant case after Park was United States
v. Starr,82 also testing the viability of the "objectively impossible"
defense. 3 In this case, also from the Ninth Circuit, the secretary-
treasurer of Cheney Brothers Food Corporation, Dean Starr, had
particular management responsibility over the sanitation of the
corporation's warehouses.' The clearing of a nearby field resulted in
a rodent infestation. 5 The secretary-treasurer first attempted to argue
that it would have been "objectively impossible" for him to foresee
such a chain of events, but the appellate court agreed with the district
75. 535 F.2d 508 (9th Cir. 1976).
76. See id. at 509.
77. Id. at 511.
78. Id. at 510.
79. Id. at 511.
80. Id.
81. See Fleder, Farquhar & Scarlett, supra note 13, at 24.
82. 535 F.2d 512 (9th Cir. 1976).
83. See id. at 512.
84. This specific management responsibility was distinct from that which accompanied
the positions of the defendant executives in Park and Dotterweich where the executive
defendants were more attenuated from the underlying criminal misconduct. See id. at 514.
85. Id. ("The warehouse had been infested with mice after an adjoining field was
plowed for farming.").
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court that someone exercising the Park standard of the highest
"foresight and vigilance" would have been able to predict and prevent
this outcome." Next, Starr argued that prevention on his part was
"objectively impossible" because, after becoming aware of the rodent
problem, he specifically instructed one of his employees to take
measures to rectify the situation and that the employee simply did not
carry out the orders.' Even this was not sufficient in the court's eyes
since the secretary-treasurer did not attempt to ensure that the
employee had followed orders until the FDA conducted a second
inspection of the facility a full month after the unsanitary conditions
were originally discovered. 8 At sentencing, the secretary-treasurer
was ordered to pay $200 for each of the three counts of adulteration.
However, while only a few cases helped advance an
understanding of how courts should apply the doctrine, it was during
this same span in the late 1970s and early 1980s that procedural norms
arose as well. Perhaps the most important of these procedures was the
"305 hearing," a preliminary hearing required by FDCA section 305"
between the FDA and the person accused of committing a prohibited
act." Section 305 is titled "Hearing Before Report of Criminal
Violation" and reads:
Before any violation of this chapter is reported by the Secretary
to any United States attorney for institution of a criminal
proceeding, the person against whom such proceeding is
contemplated shall be given appropriate notice and an
opportunity to present his views, either orally or in writing, with
regard to such contemplated proceeding.92
These hearings between the accused and the FDA were of
critical importance because they were the first time the accused could
confront his accusers. More importantly, they gave the accused
individual the chance to stop a full DOJ investigation before it began
and, in some cases, actually succeeded." "There is only one tactic in
preparing for a Section 305 hearing and that is to put together
sufficient information to convince the District Director either that a
86. See id. at 515-16.
87. Id. at 514 ("[Mr. Starr's assistant treasurer] reprimanded the warehouse janitor,
Marks, and ordered him to make corrections. Marks had not complied as of the second
inspection one month later.").
88. See id. at 516.
89. Id. at 514.
90. 21 U.S.C. § 335 (2006).
91. See id. § 331 for a list of acts currently prohibited by the FDCA.
92. Id. § 335.
93. See Fleder, Farquhar & Scarlett, supra note 13, at 28.
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violation did not occur or that, if it did, the circumstances are such
that prosecution would accomplish no real purpose."94
Yet, despite the importance of this hearing opportunity, in the
1991 case Kent v. Benson,"s the Eleventh Circuit reexamined the
original Dotterweich case and, looking past the more famous
principles that carried through to Park, concluded that a 305 hearing
is technically not required in Park doctrine prosecutions.9 6 This
perspective did, in fact, have precedent even before Dotterweich, but
not on a national scale. The reasoning behind this view was more
thoroughly explained by the Seventh Circuit in 1998:
When a defendant is morally culpable for failing to know or
guess that he is violating some law (as would be the case of
someone who committed a burglary without thinking-so
warped was his moral sense-that burglary might be a crime),
we rely on conscience to provide all the notice that is
required.... And sometimes, though the law is obscure to the
population at large and nonintuitive, the defendant had a
reasonable opportunity to learn about it, as in the case of
persons engaged in the shipment of pharmaceuticals who run
afoul of the criminal prohibitions in the federal food and drug
laws.98
This trend continued all the way to codification. As of April 1, 2011,
the FDA formally removed the requirement to offer 305 hearings to
potential Park defendants."
Despite its early use at the FDA, by the late 1980s, Park
prosecutions had become much rarer. While part of the reduction in
enforcement may be credited to the overall decrease in agency power
under the Reagan administration," some former DOJ prosecutors
credit this drop-off to limitations of departmental resources, and,
more importantly, to the overriding view in the Department that the
94. Raymond D. McMurray, Section 305 Hearings-Defense Considerations, 31 FOOD
DRUG COSM. L.J. 386, 388 (1976) (discussing the primary strategies and tactics to consider
after notification of a 305 hearing with the FDA).
95. 945 F.2d 372 (11th Cir. 1991).
96. See id. at 373 (presumably reading Dotterweich's discussion of defendant's request
for a 305 hearing: "We agree ... that the giving of such an opportunity, which was not
accorded to Dotterweich, is not a prerequisite to prosecution.").
97. See United States v. Commercial Creamery Co., 43 F. Supp. 714, 715 (E.D. Wash.
1942) (explaining that 305 hearings are technically administrative in nature and therefore
their absence does not divest a court of its jurisdiction).
98. United States v. Wilson, 159 F.3d 280, 295 (7th Cir. 1998).
99. See 21 CFR § 7.84(a)(3) (2011).
100. See Edmund L. Andrews, A Scandal Raises Serious Questions at the F.D.A., N.Y.
TIMES, Aug. 13, 1989, at F11.
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sanctions imposed on convicted Park defendants were simply not
worth the effort necessary to bring the actions in the first place.
10
Fueling this view was frustration with federal judges who understood
Title 18 offenses much better than the FDCA, as well as judges who
simply believed that, in light of the overloaded circuit dockets, Park
prosecutions were more appropriately handled by civil penalties.'o
In response to the 1989 generic drug scandal, Congress urged the
FDA to implement enhanced oversight of its criminal investigation
operations.10 3 The congressional pressure resulted in the creation of
the Office of Criminal Investigations ("OCI"), which was tasked with
reporting incidents up to DOJ."o' With DOJ determining which cases
should be pursued, the established "bottom up" prosecution
paradigm that had prevailed at the FDA became a thing of the past.
0
C. Renaissance and the Exclusion Authority
After nearly two decades of disuse, the Park doctrine was
recently put back into play by the FDA and DOJ. In 2007, HHS
secured a guilty plea from the Purdue Frederick Company
("Purdue") for the felony of "misbranding OxyContin, a prescription
opiod [sic] pain medication, with the intent to defraud or mislead."
10
From this corporate conviction arose additional guilty pleas from
three of Purdue's former top executives for the misbranding in their
positions as responsible corporate officers, each a misdemeanor
offense.'0 7 The executives presumably made their plea decision on the
assumption that any penalty or sanction assessed to them personally
would be in keeping with those from traditional (but now distant)
Park convictions. However, in response to the pleas, HHS OIG
101. See Fleder, Farquhar & Scarlett, supra note 13, at 30.
102. Id. at 30, 32.
103. See Criminal Investigations, History, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/iceci/criminalinvestigations/ucml
2 304 1.htm (last visited Jan. 15, 2013).
The 1989 generic drug scandal was revealed when it was discovered that FDA officials had
been accepting bribes from certain generic drug companies in exchange for speedy reviews
during the drug approval process. See id. The findings led to major criticism from the
public and Congressional oversight committees. See id.
104. Id.
105. See Fleder, Farquhar & Scarlett, supra note 13, at 33.
106. United States v. Purdue Frederick Co., 495 F. Supp. 2d 569, 570 (W.D. Va. 2007).
107. See Friedman v. Sebelius, 755 F. Supp. 2d 98, 101 (D.D.C. 2010) The three
executives in question were the former Chief Executive Officer Michael Friedman,
Executive Vice President and Chief Legal Officer Howard R. Udell, and Chief Scientific
Officer Paul D. Goldenheim. Id. at 101 n.5. They were originally each given a term of
exclusion for twenty years, but HHS OIG revised the terms to fifteen years after the
executives produced mitigating evidence demonstrating that they had been fully
cooperative with law enforcement officials. Id. at 103.
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issued orders of exclusion for the three executives, each with a term
of fifteen years.108 After a Departmental Appeals Board reduced the
term to twelve years, the executives appealed the decision to the
federal courts where the decision was affirmed by the United States
District Court for the District of Columbia'09 and reaffirmed by the
D.C. Circuit.o10
The doctrine was used again in securing a 2009 guilty plea from
executives at Chemnutra, Inc. for selling misbranded pet food."'
Executives at Syntheses, Inc. also pled guilty in 2009 while facing a
Park prosecution for the off-label promotion of a specific type of
bone cement.112 In early 2011, former KV Pharmaceutical Co. CEO
Marc Hermelin pled guilty to two counts of being the responsible
corporate officer in connection with a failure to prevent and correct
the distribution of oversized morphine sulfate pills.' Hermelin was
excluded from interacting with any entity that does business with a
federal health care program for a term of twenty years."4
In a surprisingly aggressive use of the Park approach in 2011,
HHS OIG unexpectedly informed Forest Laboratories, Inc. CEO,
Howard Solomon, that it intended to use the exclusion authority
against him in connection with the company's 2010 guilty plea to a
misdemeanor for off-label marketing of the popular antidepressants
Celexa and Lexapro."is Although the corporation's plea agreement
included $313 million in fines for the violations, it contained nothing
108, Id. at 103.
109. Id. at 117,
110. Friedman v. Sebelius, 686 F.3d 813 (D.C. Cir. 2012) (affirming the lower court's
decision to exclude the corporate officers, but reversing as to the length of time of the
exclusion).
111. DANIEL R. MARGOLIS, MARK R. HELLERER & AARON S. DYER, PILLSBURY
WINTHROP SHAW PITTMAN LLP., CLIENT ALERT: FDA TO BRING MORE CRIMINAL
CHARGES AGAINST EXECUTIVES FOR COMPANIES' FDCA VIOLATIONS 2 (2010),
http://www.pillsburylaw.com/siteFiles/Publications/D98DF569EA917C29C8CE406316FA2
13C.pdf.
112. See United States v. Huggins, No. 09-403-3, 2011 U.S. Dist. LEXIS 142869, at *4-
(E.D. Pa. Dec. 13, 2011); United States v. Higgins, No. 09-403-4, 2011 U.S. Dist. LEXIS
140343, at *25-26 (E.D. Pa. Dec. 7, 2011).
113. See Joe Whittington & Andrew Harris, Ex-KV Pharmaceutical CEO Hermelin
Pleads Guilty to Drug Label Law Breach, BLOOMBERG (Mar. 10, 2011), http://www.
bloomberg.com/news/2011-03-10/ex-kv-pharmaceutical-ceo-hermelin-pleads-guilty-to-
drug-label-law-breach.html.
114. See Jim Doyle, After Long, Strange and Profitable Trip, Ex-KV Chief Resigns in
Scandal, ST. LOUIs DISPATCH, Nov. 18, 2010, at Al, available at http://www.stltoday.com/
business/local/articleabb3lb54-2521-515e-b6Od-1603fe5f90a2.html.
115. See Alicia Mundy, US. Efforts to Remove Drug CEO Jolts Firms, WALL ST. J.,
Apr. 26, 2011, at Al.
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about Mr. Solomon.116 This unexpected use of the Park approach in
conjunction with the exclusion authority shocked the corporation.1 17
According to a top health care white-collar defense attorney, the
action against Mr. Solomon was a "game changer.""1
This increase in Park actions stems in large part from a
reinvigorated emphasis on adversarial regulatory tactics by the FDA
and the need for a more effective criminal investigation capacity. This
renewed emphasis grew out of criticism that began in 2009 with a
report from the GAO critiquing the FDA's management of its
criminal investigations operation."' GAO released another report in
January 2010 criticizing the FDA's capacity to regulate criminal
conduct in the pharmaceutical sector. 120 In response to this mounting
criticism, FDA Commissioner Margaret Hamburg wrote the
aforementioned letter to Senator Grassley in March 2010,121 formally
committing the FDA to improving their utilization of both the Park
doctrine and exclusion authority.1
If this was not enough to place drug manufacturers on notice, on
April 22, 2010, in a speech to the Food and Drug Law Institute, the
FDA's Chief Counsel for Litigation, Eric Blumberg, speaking about
an increased focus on executive prosecution, said to a room full of
industry lawyers, "Very soon, and I have no one particular in mind,
some corporate executive is going to be the first in a long line ... . So
it's going to happen." 1 23 Furthermore, in February 2011, the FDA
finally released a set of criteria that Commissioner Hamburg had
mentioned in the Grassley letter, which are to be used "for
consideration in selection of misdemeanor prosecution cases."124 The
criteria, located in section 6-5 of the FDA's online Regulatory




119. See U.S. GOv'T ACCOUNTABILITY OFFICE, GAO-09-807, OVERSIGHT OF
CLINICAL INVESTIGATORS: ACTION NEEDED TO IMPROVE TIMELINESS AND ENHANCE
SCOPE OF FDA's DEBARMENT AND DISQUALIFICATION PROCESSES FOR MEDICAL
PRODUCT INVESTIGATORS (2009), available at http://www.gao.gov/new.items/d09807.pdf.
120. See GAO Report, supra note 4.
121. Letter from Comm'r Margaret Hamburg to Sen. Charles Grassley, supra note 5.
122. Id.
123. FDA Deputy Chief Counsel for Litigation Eric Blumberg, Remarks at the Food
and Drug Law Institute Annual Conference (Apr. 22, 2010), available at http://www.
fairwarning.org/2010/08/fda-eyes-prosecutions-to-toughen-enforcement/. Interestingly,
Blumberg was a contributing author for one of the Government's briefs in the original
Park case. See Fleder, Farquhar & Scarlett, supra note 13, at 39.
124. Letter from Comm'r Margaret Hamburg to Sen. Charles Grassley, supra note 5, at
2.
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Considerations for Park Doctrine Prosecutions." 5 The heart of the
guidelines reads as follows:
When considering whether to recommend a misdemeanor
prosecution against a corporate official, consider the
individual's position in the company and relationship to the
violation, and whether the official had the authority to correct
or prevent the violation. Knowledge of and actual participation
in the violation are not a prerequisite to a misdemeanor
prosecution but are factors that may be relevant when deciding
whether to recommend charging a misdemeanor violation.
Other factors to consider include but are not limited to:
1. Whether the violation involves actual or potential harm to
the public;
2. Whether the violation is obvious;
3. Whether the violation reflects a pattern of illegal behavior
and/or failure to heed prior warnings;
4. Whether the violation is widespread;
5. Whether the violation is serious;
6. The quality of the legal and factual support for the
proposed prosecution; and
7. Whether the proposed prosecution is a prudent use of
agency resources.2 6
From a practical standpoint, whether these criteria give any
actual insight into how FDA attorneys will evaluate potential Park
claims any differently than other criminal claims has been called into
question. 127 Nevertheless, for the purposes of this Comment, the mere
fact that the criteria have been established and distributed adds to the
body of evidence suggesting that Park prosecutions will become more
prevalent in the near future.
The odd marriage between the Park doctrine and HHS's
exclusion authority is the most puzzling result of this new direction in
FDA and HHS OIG prosecution. In essence, an exclusion is the
separation of an individual or corporation from federal health care
operations, meaning that an excluded entity is prohibited from
125. See FOOD & DRUG ADMIN., FDA REGULATORY PROCEDURES MANUAL,
INSPECTIONS, COMPLIANCE, ENFORCEMENT, AND CRIMINAL INVESTIGATIONS, § 6-5-3,
at 6-49 to 6-50 (2011), available at http://www.fda.gov/ICECI/ComplianceManuals/
RegulatoryProceduresManuallucml76738.htm#SUB6-5-3.
126. Id.
127. See, e.g., Anne K. Walsh, FDA Finally Releases "Non-Binding" Park Doctrine
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receiving any payments from any federal health care program 28
(Medicare, Medicaid, etc.) for a specified term.129 Additionally, no
payment may be made to any entity employing or contracting with an
excluded individual or company."30 Exclusion and its cousin,
debarment, are two of the most potent tools that HHS has to enforce
industry regulations in the health care and pharmaceutical
industries."' The main difference between the two penalties is scope.
Exclusion is effectively an exile from the health care industry since
excluded individuals may not work for, or with, any company that
receives federal health care funding. 32 Debarment, on the other
hand, is still restrictive, but only prohibits a debarred individual from
"providing services in any capacity to a person that has an approved
or pending drug product application."' 3 3 In other words, debarment
primarily prevents individuals from working for or with drug
companies, while exclusion prevents individuals from working for or
with almost any company that provides health services. HHS
maintains publicly available lists of individuals and entities that have
either been excluded or debarred, thus preventing them from
reentering the health care market.134
128. A federal health care program is defined as "any plan or program providing health
care benefits, whether directly through insurance or otherwise, that is funded directly, in
whole or part, by the United States Government (other than the Federal Employees
Health Benefits Program), or any State health care program as defined in this section." 42
C.F.R. § 1001.2(d) (2011).
129. 42 U.S.C. § 1320a-7 (2006).
130. See id. §§ 1395y(e), 1396a(a)(39); 42 C.F.R. § 1001.1901 (2011).
131. Exclusion is often referred to as a "devastating" punishment. See, e.g., Joe
Carlson, Career-Devastating Punishment: Four Former Synthes Execs Excluded from
Medicare for Roles in Surgery Case, MODERNHEALTHCARE.COM (Oct. 20, 2012, 12:01
AM), http://www.modernhealthcare.comlarticle/20121020/MAGAZINE/310209971
(subscription required); Violations of Corporate Integrity Agreement Trigger Divestiture
Action by HHS OIG, SKADDEN.COM (June 14, 2012), http://www.skadden.com/
newslettersNiolations ofCorporateIntegrity-AgreementTrigger_DivestitureAction_
byHHSOIG.pdf (describing exclusion as "the death knell for careers and companies
alike").
132. See Exclusions, Background Information, DEP'T HEALTH & HUMAN SERVS.,
OFF. INSPECTOR GEN., https://oig.hhs.gov/exclusions/background.asp (last visited Oct. 27,
2012).
133. 21 U.S.C. § 335a(a)(2) (2006).
134. See Exclusions Program, DEP'T HEALTH & HUMAN SERVs., OFF. INSPECTOR
GEN., http://oig.hhs.gov/exclusions/index.asp (last visited Jan. 19, 2013); Inspections,
Compliance, Enforcement, and Criminal Investigations, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/ICECI/EnforcementActions/FDADebarmentList/default.htm (last
visited Jan. 19, 2013).
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Exclusion is effectively a "death sentence" for a career in the
health care industry.135 In 2010, the federal government paid the bill
for nearly thirty percent of all national health expenditures, thus
making it difficult to identify health companies or health service
providers in America that receive no money from any governmental
health program.136 Many state medical assistance programs are
covered by this ban as well because they operate on grant funding
from the federal government." ' 42 U.S.C. § 1396a(a)(39) insures that
these state-run but largely federally funded programs do not offer
excluded individuals a loophole to remain connected to the federal
health system.3 8 In order to be eligible for the flow of federal health
grants coming out of various federal agencies,
[a] State plan for medical assistance must provide that the State
agency shall exclude any specified individual or entity from
participation in the program under the State plan for the period
specified by the Secretary, when required by him to do so
pursuant to section 1320a-7 of this title or section 1320a-7a of
[Title 42]. "1
With this provision, the federal health care system becomes largely
sealed off from individuals who are excluded by the HHS Secretary.
Although only recently coupled with the Park doctrine, the
exclusion authority originated on January 4, 1977, when, after
mounting pressure surrounding the insufficiency of existing penalties
against Medicare and Medicaid fraud and abuse, two democratic
congressmen, Representative Paul G. Rogers from Florida 4 0 and
Representative Dan Rostenkowski from Illinois, introduced the
Medicare-Medicaid Anti-Fraud and Abuse Amendments in the
House Ways and Means Subcommittee. 4' The timing of the bill's
passage relative to the 1975 Park case is significant. Had the case
135. ScoTT MCBRIDE & SUMMER D. SWALLOw, BNA's HEALTH CARE FRAUD
REPORT: THE KIss OF DEATH: OIG's EXCLUSION AUTHORITY 1 (Jan. 12, 2011), http://
www.bakerlaw.com/files[Uploads/Documents/News/Articles/HEALTHCARE/2011/HCFr
audReport McBrideSwallow 1-2011.pdf.
136. CrRS. FOR MEDICARE & MEDICAID SERVS., NATIONAL HEALTH
EXPENDITURES 2010: SPONSOR HIGHLIGHTS 2-4 (2010), http://www.cms.gov/
NationalHealthExpendData/downloads/sponsors.pdf.
137. 42 U.S.C. § 1396a(a)(39) (2006).
138. Id.
139. Id.
140. Representative Rogers was one of the most important legislators for health care
issues of his time, earning him the nickname "Mr. Health." See Dennis Hevesi, Paul G.
Rogers, 87, Dies; 'Mr. Health' in Congress, N.Y. TIMES, Oct. 15, 2008, at A33.
141. Jennifer 0. Sullivan, Cong. Research Serv., 77-243 ED, Medicare-Medicaid Anti-
Fraud and Abuse Amendments-P.L. 95-142 3 (Nov. 16, 1977).
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arisen after Congress passed the Medicare-Medicaid Anti-Fraud and
Abuse Amendments, the Court would have been operating under
different circumstances. Because the exclusion penalty did not exist
until 1977, two years after the Court issued its ruling in Park, the
Justices were unable to consider the extent to which the Park
doctrine could be used. Indeed, at the time Dotterweich and Park
were decided, this theory of liability would only have resulted in
nominal monetary penalties to the defendants. 142
It was not until 1996 with the passage of the mammoth Health
Insurance Portability and Accountability Act ("HIPAA") that the
modern exclusion authority came into existence.143 The Act increased
the ability of HHS OIG to use exclusions by: "(1) broadening the
OIG's mandatory exclusion authority; (2) establishing minimum
exclusion periods for certain discretionary exclusions; and (3)
establishing a discretionary exclusion authority applicable to owners,
officers and managers of sanctioned entities."1" The third category is
at issue here. Under section 1128(b)(15) of the Social Security Act,
HHS is statutorily permitted to exclude someone merely by virtue of
his or her role in a sanctioned corporate entity.'45 Since Park
established that such responsible corporate officers can be held liable
for conduct that the officer neither committed nor knew of, 4 6 this
particular flavor of exclusion can become particularly worrisome. The
ability for government prosecutors to establish exclusion eligibility for
officers and managers based on the corporation's sanction poses
legitimate liability concerns for managers and officers who oversee
regulated activity. In late 2010, HHS OIG made available guidance of
this particular type of exclusion (codified under section
1128(b)(15)). 47
In essence, the exclusion authority, with its ability to effectively
end an individual's career in the health care sector, gives HHS OIG
significant leverage in collecting fines and arriving at favorable
settlements. In the 2011 fiscal year, HHS OIG brought 723 criminal
142. See infra text accompanying notes 215-16.
143. Health Insurance Portability and Accountability Act (HIPAA), Pub. L.
No. 104-191, § 211, 110 Stat. 1936, 2003-05 (1996) (codified as amended at 29 U.S.C.
§ 1181 (2006)).
144. McBride & Swallow, supra note 135, at 2.
145. Social Security Act § 1128,42 U.S.C. § 1320a-7(b)(15) (2006).
146. United States v. Park, 421 U.S. 658,673 (1975).
147. See DEP'T. OF HEALTH & HUMAN SERVS., OFFICE OF INSPECTOR GEN.,
GUIDANCE FOR IMPLEMENTING PERMISSIVE EXCLUSION AUTHORITY UNDER SECTION
1128(B)(15) OF THE SOCIAL SECURITY ACT (Oct. 20, 2010), http://oig.hhs.gov/fraud/
exclusions/files/permissive exclunder1128bl15j0192010.pdf.
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actions against individuals or entities "engaged in crimes against HHS
programs."148 More than 600 of these were criminal actions for health-
care-related offenses, which netted $3.6 billion in expected
recoveries. 149
II. THE MENS REA CONTROVERSY OVER THE PARK DOCTRINE
One of the primary debates surrounding the use of the Park
doctrine is its capacity to subject individuals to an exclusion or
debarment via strict liability."'o But the question underlying this
controversy is more appropriately framed as one of the responsible
officer defendant's mens rea. While the statutes and case law cling to
a strict liability standard, there are still strong arguments that a
negligence (or a high negligence) standard is more in line with the
pertinent case patterns and legislative history. This inquiry is
particularly important since Park and Dotterweich were both decided
when the exclusion authority was wholly unavailable to the regulators
at HHS."'5 With such a dramatic penalty now available to
administrative agencies for certain FDCA and health care offenses,
determining whether the doctrine emphasizes strict liability or,
alternatively, a high form of negligence will be useful in
understanding how regulators view the doctrine's mechanics in
modern practice.
A. Arguments for a Negligence Standard
The most robust argument that a high negligence standard,
rather than a strict liability standard, is being used is borne out by the
case law. In Park, there is technically no mention of a strict liability
148. DEP'T. OF HEALTH & HUMAN SERVS., OFFICE OF INSPECTOR GEN.,
SEMIANNUAL REPORT TO CONGRESS APRIL 1, 2011-SEPTEMBER 30, 2011, at i (2011),
http://oig.hhs.gov/reports-and-publications/archives/semiannual/2011/fall/HHS-OIG-SAR-
Fall2011.pdf.
149. Id. at III-1.
150. See, e.g., Abrams, supra note 12, at 464-67 (outlining three different
interpretations of the conduct standards set up by Park and noting that the most common
is a strict liability standard). But see, e.g., United States v. New England Grocers Supply
Co., 488 F. Supp. 230, 235-37 (D. Mass. 1980) ("Under this [alternative] interpretation, the
impossibility defense would serve as an affirmative defense, incorporating an objective
element-use of extraordinary care-into a strict liability offense."); Corporate Crime:
Regulating Corporate Behavior Through Criminal Sanctions, 92 HARv. L. REV. 1227,
1264-65 (1979) (arguing that "[w]ith the impossibility defense, the strict liability standard
as applied to indirect actors becomes in practice a standard of extraordinary care").
151. Park was decided in 1975, two years before Congress created the exclusion
authority in the Office of the Secretary of HHS. See Medicare-Medicaid Anti-Fraud and
Abuse Amendments, Pub. L. No. 95-142, § 7(a), 91 Stat. 1175, 1192-93 (1977).
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standard. 15 2 In fact, the majority committed the final three paragraphs
of its opinion to the type of notice that Mr. Park should have gained
in dealing with his hierarchy of subordinates."' The Court relied on
evidence whose very "purpose was to demonstrate that [Park] was on
notice that he could not rely on his system of delegation to
subordinates to prevent or correct insanitary conditions."s154
Regardless of whether Mr. Park did indeed heed such notice, the
Court answered in the negative."' However, the fact that the Court
took the time to explain the importance of notice in Mr. Park's
situation seems to belie any definitive reliance on strict liability. If
strict liability were in full effect, notice would not be necessary at all.
Furthermore, the majority emphasized their view that "[t]he duty
imposed by Congress on responsible corporate agents is, we
emphasize, one that requires the highest standard of foresight and
vigilance."'5 6 As the dissent quickly points out about the majority's
use of the terms "notice" and "duty," "This is the language of
negligence."5 '
In United States v. Y. Hata & Co., an important doctrinal case
from 1976, the Ninth Circuit similarly held a responsible officer liable
because he did not carry out his duty to protect his warehouse from
known bird entry to the extent that he should have.'" The same duty
and notice pattern was established in United States v. Starr when the
Ninth Circuit found that Mr. Starr's position in a food management
company imputed on him a duty to act with "foresight and vigilance"
in order to correct the infestation of rodents of which he was aware.19
152. However, three years after the Park opinion was handed down, the Supreme
Court heard United States v. U.S. Gypsum Co., 438 U.S. 422 (1978), and attempted to
clarify its position in Park. Importantly, between Park and Gypsum, only one membership
change occurred on the Court when Justice Stevens replaced Justice Douglas in late 1975.
Gypsum partly addressed the fit between a scheme of vicarious strict liability and criminal
violations of the Sherman Act. In a footnote to the Gypsum opinion (which overall
illustrated a general distaste for vicarious strict liability in this context, see Gypsum 438
U.S. at 440-43), the Court indirectly clarified that Park had set up a strict liability
standard, holding that "antitrust laws differ in this regard from, for example, laws designed
to insure that adulterated food will not be sold to consumers. In the latter situation,
excessive caution on the part of producers is entirely consistent with the legislative
purpose." Id. at 441-42 n.17.
153. United States v. Park, 421 U.S. 658,678 (1975).
154. Id. at 677-78.
155. Id. at 678.
156. Id. at 673.
157. Id. at 679 (Stewart, J., dissenting).
158. See United States v. Y. Hata & Co., 535 F.2d 508,511 (9th Cir. 1976).
159. United States v. Starr, 535 F.2d 512, 515 (9th Cir. 1976) ("[Tlhe duty of 'foresight
and vigilance' requires the defendant to foresee and prepare for such an occurrence,
whether it be deemed 'natural' or 'artificial.' " (citations omitted)).
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Similarly, in a 1985 action against Eli Lilly, the pharmaceutical
company's Director for Medicine, Research and Development in the
U.K. pled nolo contendere to charges that he neglected his duty to
report four deaths and six illnesses caused by the company's drug
Oraflex.1s The common theme throughout these cases is that the
prosecutions were all predicated on the premise that the executives
had or should have had notice of the criminal misconduct, but chose
not to adequately act on that knowledge. These cases, all descendants
of Park, comprise an odd progeny for the Supreme Court case that is
reputed for its ability to use strict liability in order to reach officers
who otherwise would have no connection to the underlying criminal
conduct.
Interestingly, most commentary on the Park doctrine fails to
notice that, although the law may have indeed permitted FDA to
prosecute responsible officers on a pure strict liability basis (where no
knowledge or intent existed), FDA actually had an institutional
practice of ensuring that prosecutions were only brought when there
was evidence that the responsible corporate officer knew or should
have known about the problematic conditions.'6 ' In an obscure
journal article from 1976, Sam Fine, the former FDA Associate
Commissioner for Compliance, wrote, "We insist ... that our
prosecution recommendations include a factual record which
demonstrates that every individual charged either knew or should
have known of the violative conditions set forth, and was in a position
to do something about those conditions but failed to do so."162 This
belies the need for strict liability. If the letter of the law has
consistently expressed the preference for a strict liability standard,
but FDA and DOJ have only actually brought cases where the fact
patterns fit a lower negligence standard, it sheds some light on the
confusion that has steadily built around the precise dynamics of the
Park doctrine's conduct requirements.
Moreover, there is evidence that the original Dotterweich Court
was acutely aware of the door they were opening to strict liability and
in turn showed sensitivity to the fact that they were handing
government prosecutors a very large legal club. In discussing the
difficulty of determining who should be liable under this new strict
vicarious liability theory, the Dotterweich Court noted that "[i]n such
160. See Fleder, Farquhar & Scarlett, supra note 13, at 24.
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matters the good sense of prosecutors... must be trusted."' And
then in the majority's final paragraph of the opinion, it reiterated,
"Our system of criminal justice necessarily depends on 'conscience
and circumspection in prosecuting officers.' "" The Government
was, no doubt, aware of this dynamic when it wrote in its brief for
Park that it would only bring cases when there'was enough evidence
to prove that the individual defendant had some notice of the
underlying misconduct:
Even if investigation discloses the elements of liability, and
indicates that an official bears a responsible relation to them,
the agency will not ordinarily recommend prosecution unless
that official, after becoming aware of possible violations, often
(as with Park) as a result of notification by FDA, has failed to
correct them or to change his managerial system so as to
prevent further violations.'
A final point of support for the negligence standard can be found
in the legislative history of the FDCA itself. In the Senate report that
accompanied the original bill, the authors were clear that liability
should not be extended to directors or officers who authorized
subordinates to perform lawful duties when those subordinates took
it upon themselves to act unlawfully.' 66 Under a strict liability
standard, liability could easily reach officers and directors who
engaged in this form of delegation. Thus, if strict liability had been
the preference of Congress, it may be presumed that a discussion of
the nature of an officer's relation to a criminal offense would not
appear so explicitly in the legislative history. Even more revealing is
the fact that draft versions of the FDCA included express language
implementing a strict liability standard for directors and officers that
was ultimately removed in the bill's final iteration. The removed
language read:
[W]henever a corporation or association violates any of the
provisions of this Act, such violation shall also be deemed to be
163. United States v. Dotterweich, 320 U.S. 277,285 (1943).
164. Id. (internal quotation marks and citations omitted).
165. Plaintiff's Summary Judgment Reply Brief at 13, Friedman v. Sebelius, 755 F.
Supp. 2d 98 (D.D.C. 2010), rev' d, 686 F.3d 813 (D.C. Cir. 2012) (No. 1:09-cv-02028-ESH)
(emphasis added) (quoting Brief of United States at 31-32, United States v. Park, 421 U.S.
648 (1975) (No. 74-215)).
166. S. REP. No. 73-493, at 22 (1934) ("It is not, however, the purpose of [section
18(b)] to subject to liability those directors, officers, and employees, who merely authorize
their subordinates to perform lawful duties and such subordinates, on their own initiative,
perform those duties in a manner which violates the provisions of the law.").
9752013]
THE NEW PARK DOCTRINE
a violation of the individual directors, officers, or agents of such
corporation or association who authorized, ordered, or did any
of the acts constituting, in whole or in part, such violation.'67
The fact that this language, which so clearly and definitively sets up a
strict liability standard, was removed in the bill's final version
demonstrates that Congress had a clear opportunity to include a strict
liability standard, but made a conscious decision not to do so." This
type of negative construction is precisely the method the Court used
in interpreting the meaning of the Taft-Hartley Act's silence
regarding the president's authority to seize private industrial assets in
order to resolve labor disputes during times of war in the Steel
Seizure Cases."9
B. Arguments for a Strict Liability Standard
The pattern of notice and duty and the legislative history raises
the question: is the famous strict liability standard of the Park
doctrine a misunderstanding? While the above evidence is interesting,
this Comment argues that the strict liability standard is still the
correct approach to understanding the doctrine. There are three main
observations that support this strict liability reading. First, strict
liability was definitively the standard that the Court in Dotterweich
announced when it determined that the purpose of the FDCA was to
protect the public welfare and "enlarge and stiffen the penal net" that
shielded it from dangerous conditions, however accidental or
innocent their cause. 70 This interpretation is consistent with common
public welfare statutes that penalize violations of laws that protect the
public well being by punishing even those individuals who lacked any
167. Dotterweich, 320 U.S. at 291 (Murphy, J., dissenting) (citing S. 5, 75th Cong. § 2(f)
(1937); S. 5, 74th Cong. § 707(b) (1936); S. 5, 74th Cong. § 709(b) (1935); S. 2000, 73d
Cong. § 18(b) (1934); S. 2800, 73d Cong. § 18(b) (1934); S. 1944, 73d Cong. § 18(b) (1933)).
168. This form of reasoning is not unfamiliar to congressional and Supreme Court
observers. In Justice Hugo Black's formalist majority opinion in the Steel Seizure Case that
condemned the President's wartime authority to seize private steel industry assets, he
reasoned that, since Congress had formally "rejected an amendment [to the Taft-Hartley
Act] which would have authorized such governmental seizures in cases of emergency," it
indicated that Congress had thereby not authorized the President to take such actions on
his own initiative. Youngstown Sheet & Tube Co. v. Sawyer, 343 U.S. 579,586 (1952).
169. See id. (concluding that Congress had definitely rejected the President's power to
resolve labor disputes via the seizure technique by defeating an amendment to the Taft-
Hartley Act in 1947).
170. Dotterweich, 320 U.S. at 282; see also United States v. Y. Hata & Co., 535 F.2d
508, 511 (9th Cir. 1976) ("One maintaining far less than the requisite 'highest standard of
foresight and vigilance' would have recognized as early as August 1971 that
implementation of a wire cage system would substantially, if not completely, prevent
access by thieving and untidy birds.").
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intent to cause the violation to occur.'7 1 It is frustrating for those who
understood Dotterweich this way that the Court in Park, the formal
extrapolators of Dotterweich, did not treat this issue as clearly as it
could have.172
Second, § 331 of the FDCA (the section that defines prohibited
acts) does not set up a scheme with a definitive mens rea
requirement." 3 Section 331 begins with the language: "The following
acts and the causing thereof are prohibited.... "I7 These words do
not contain any intent or knowledge requirement, but instead operate
only to outlaw the specific enumerated actions."' Thus, a court need
not consider any intent or knowledge factors when determining
whether a violation occurred because the statute contains no such
requirement. In determining culpability under the FDCA, all a court
needs to decide is whether the facts show that one of the prohibited
actions occurred.176
Additional support for attributing a strict liability standard to the
Park doctrine is the falsity of the "objectively impossible defense."
The objective impossibility defense is supposed to give responsible
officers an opportunity to demonstrate that, despite their best efforts,
171. See, e.g., Clean Water Act § 101, 33 U.S.C. § 1251 (2006). The Senate Report that
accompanied the Clean Water Act noted specifically that "[cjriminal liability
shall ... attach to any person who is not in compliance with all applicable Federal, State
and local requirements and permits and causes a POTW [publicly owned treatment works]
to violate any effluent limitation or condition in any permit issued to the treatment
works." S. REP. No. 99-50, at 29 (1985). In United States v. Weitzenhoff, 35 F.3d 1275 (9th
Cir. 1993), the Ninth Circuit held that when a person "knowingly engages in conduct that
results in a permit violation, regardless of whether the polluter is cognizant of the
requirements or even the existence of the permit," that person will be guilty of the
violation. Id. at 1284; see also United States v. Int'l Minerals & Chemical Corp., 402 U.S.
558, 565 (1971) (holding that actual knowledge of an environmental regulation designed to
reduce the risk of handling hazardous material is not a necessary condition for establishing
liability).
172. The term "strict liability" does not appear once in Park. The Court only
announced a conduct standard as follows:
The Act does not, as we observed in Dotterweich, make criminal liability turn on
'awareness of some wrongdoing' or 'conscious fraud.' The duty imposed by
Congress on responsible corporate agents is, we emphasize, one that requires the
highest standard of foresight and vigilance, but the Act, in its criminal aspect, does
not require that which is objectively impossible.
United States v. Park, 421 U.S. 658,672-73 (1975) (quoting Dotterweich, 320 U.S. at 281).
173. See Federal Food, Drug, and Cosmetic Act § 1, 21 U.S.C. §§ 301, 331 (2006)
(describing acts within the food and drug industries that constitute violations).
174. Id. § 331.
175. Id.
176. Of the fifty-four prohibited acts listed in FDCA § 331, four of them do carry
individualized knowledge requirements that do not apply to the remainder of the list. See
id. §§ 331(w), (gg), (jj)(1), (yy).
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they were helpless to prevent the criminal conduct and, at least in
name, it does so: "To establish the impossibility defense the corporate
officer must introduce evidence that he exercised extraordinary care,
but was nevertheless unable to prevent violations of the [FDCA.""
But, as was demonstrated in the earlier cases, the success of the
defense ultimately rests on the fact finder's individualized sense of
what constitutes a sufficient effort."' The fact finder enjoys the luxury
of being able to second guess the corporate official's actions. As such,
the defense has never worked in a defendant's favor.179
Furthermore, impossible actions, by definition, cannot occur. If
the defense is read in converse, it appears much less appealing to the
defendant: if it is possible for the corporate officer to have known
about and to have been able to prevent or promptly correct the
criminal misconduct, then failure to do so may result in liability. In
other words, as long as a court determines that it would have been
possible for the officer to prevent a FDCA violation, an argument of
powerlessness is overcome and liability attaches. In FDCA violations
then, if the court can come up with an operational strategy that would
have theoretically prevented the violation and the officer had not
taken this course of action, liability can be proscribed. 180
Doctrinally, the notion of something being "objectively
impossible" is convenient if the end goal is to convict those parties
who are only indirectly connected to the underlying misconduct. It is
not a measure of likelihood or probability, but only possibility. In
other words, it is a black or white determination: something either is
possible or it is not. This binary characteristic makes the entire notion
of impossibility highly unstable because it is contingent on what the
fact finder believes to be possible. It is flimsy at best and subject to
individual manipulation at worst, giving the advantage to the fact
177. United States v. Gel Spice Co., 773 F.2d 427, 434-35 (2d Cir. 1985) (quoting
United States v. New England Grocers Co., 488 F. Supp. 230,234 (D. Mass. 1980)).
178. See supra text accompanying notes 84-94.
179. A search of every case that cites Park wherein the objective impossibility defense
was raised and addressed reveals that no court, state or federal, has ever sided with a
defendant raising this argument. See United States v. Y. Hata & Co., 535 F.2d 508, 511-12
(9th Cir. 1976); United States v. Starr, 535 F.2d 512, 515-16 (9th Cir. 1976); Hujazi v.
Superior Ct. of California, No. CV 11-9219-ODW(E), 2012 WL 3076338, at *8 (C.D. Cal.
Jul. 26, 2012); United States v. Ellison, 112 F. Supp. 2d 1234, 1239 (D. Col. 2000); United
States v. Gel Spice Co. Inc., 601 F. Supp. 1205, 1213 (E.D.N.Y. 1984); United States v.
Torgian Laboratories, Inc., 577 F. Supp. 1514, 1530 (E.D.N.Y. 1984); New England
Grocers Co., 488 F. Supp. at 236-37; People v. Matthews, 9 Cal. Rptr. 2d 348, 354 (Cal. Ct.
App. 1992); McNeely v. United States, 874 A.2d 371, 388 (D.C. 2005); Waste Conversion,
Inc. v. Commonwealth, 568 A.2d 738, 743 (Pa. Commw. Ct. 1990).
180. See Y Hata & Co., 535 F.2d at 511-12.
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finder to come out where he wants. Working with the Second
Circuit's explanation of the defense,'s the fact finder must first
determine whether the actions taken by the responsible officer
constitute extraordinary care." This is essentially a subjective inquiry
since it requires the fact finder to determine whether the officer's
action (or lack of action) fell below the normal standard of conduct
for others in similar situations. This standard is akin to the reasonable
person standard, except that it asks the jury or judge to assess the
situation according to the reasonable pharmaceutical executive. If the
defendant's action fell below that reasonable executive standard, the
fact finder must then determine whether there was some other action
that could have prevented or corrected the misconduct.18 3 Objectively
speaking, it is almost always possible for an executive to know of
and/or prevent a specific act. Despite how highly unlikely it is that a
subordinate who has chosen to commit a prohibited act decides
nevertheless to tell the responsible officer of his actions, it is still
possible that the subordinate might do so, and therefore fails the
objective impossibility standard. For example, in the world of off-
label marketing, if a subordinate salesman at a pharmaceutical
company took it upon himself to market a certain drug product for an
off-label use (a FDCA prohibited act), in theory, it is still objectively
possible for the salesman to tell the responsible officer about the
illegal effort and therefore prevent the misconduct from occurring.
Thus, the argument that it was objectively impossible for the
responsible officer to know of the misconduct will not provide a
defense.
But this is where the overwhelming subjectivity of the inquiry
arises and the defense loses much of its ability to shield the officer-
defendant. In the face of all the evidence presented by the
government and the defense, the fact finder must ultimately try to
determine to what extent a given preventative action would have
been possible." It requires the fact finder to conjure some alternative
course of action and determine the possibility of its conception,
181. Gel Spice Co., 773 F.2d at 434-35.
182. Id. ("To establish the impossibility defense the corporate officer must introduce
evidence that he exercised extraordinary care, but was nevertheless unable to prevent
violations of the [FDCA]." (emphasis added)).
183. Id. ("To establish the impossibility defense the corporate officer must introduce
evidence that he exercised extraordinary care, but was nevertheless unable to prevent
violations of the [FDCA]." (emphasis added)).
184. Id. ("To establish the impossibility defense the corporate officer must introduce
evidence that he exercised extraordinary care, but was nevertheless unable to prevent
violations of the [FDCA]." (emphasis added)).
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execution, and success." The impossibility inquiry requires the fact
finder to put himself in the shoes of the officer-defendant and ask if
he would have then considered the preventative actions impossible.'"
Given this series of inquiries, and the reality that the fact finder
benefits from perfect hindsight, it should not come as a surprise that
"[tihe impossibility defense has rarely been raised, and has never
been satisfied." 87
Other evidence that Park set up a strict liability standard appears
in dicta from subsequent circuit court opinions. For example, the
Fifth Circuit, functioning in a labor law context, cited to Park's notion
of strict vicarious liability in order to hold an executive responsible
for the safety of his employees:
[I]t is a common regulatory practice to impose a kind of strict
liability on the employer as an incentive for him to take all
practicable measures to ensure the workers' safety, the idea
being that the employer is in a better position to make specific
rules and to enforce them than the agency is.'88
Earlier in 1978, the United States District Court for the Northern
District of New York made the distinction between the strict liability
standard and one with more of a negligence function. In this FDCA
adulteration case, the district court noted:
To allow the defendants to avoid liability under the Act merely
by testing samples of the product, which samples prove negative
for contamination, would be to obliterate the standard of
absolute liability imposed by the Food, Drug and Cosmetic Act
185. This is precisely how the Ninth Circuit has approached the analysis of the
impossibility defense. See Y. Hata & Co., 535 F. 2d at 511 (rejecting the defendant's
impossibility defense by holding that "[o]ne maintaining far less than the requisite 'highest
standard of foresight and vigilance' would have recognized as early as August 1971 that
implementation of a wire cage system would substantially, if not completely, prevent
access by thieving and untidy birds").
186. Id. ("A wire cage is scarcely a novel preventive device. One maintaining far less
than the requisite 'highest standard of foresight and vigilance' would have recognized as
early as August 1971 that implementation of a wire cage system would substantially, if not
completely, prevent access by thieving and untidy birds.").
187. See Corporate Crime: Regulating Corporate Behavior Through Criminal Sanctions,
supra note 150, at 1263. It is quite possible, however, that the reason the impossibility
defense has never been successfully used is that prosecutors at DOJ and HHS only choose
to bring cases where they are certain the defense will not succeed.
188. Allied Prods. Co. v. Fed. Mine Safety & Health Review Comm'n, 666 F.2d 890,
893 (5th Cir. 1982).
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and subtly inject into the statute an element of scienter, or
conscious awareness of guilt.' 9
This subtlety of the negligence standard that the district court found
lurking in the lessons of Park and Dotterweich may also help explain
the pattern of cases where a high negligence standard was
employed.'90
With government health care prosecutions on a sharp rise,191 this
split between Park doctrine explanation and execution has left an
area of growing legal importance largely grey.19 Perhaps the
ambiguity was not so worrisome when government prosecutions were
less frequent and the exclusion authority was not yet available to
HHS regulators, but with the advent of such a sweeping penalty in
combination with the higher number of suits, executives and their
corporate counsels may take a more careful look at the precise
dynamics of their compliance efforts.
III. HOW THE NEW LANDSCAPE FUNDAMENTALLY CHANGES THE
PARK CALCULUS
A. The Strict Liability Standard of Conduct in Modern Context
The combination of the Park doctrine's confusing legal standards
with its recent attachment to the exclusion penalty sets up an unusual
regulatory landscape for corporate defense teams in the
pharmaceutical and health care sectors. When the doctrine was
originally fashioned in the 1970s and 1980s, the cases against
individuals typically resulted in fines, fees, and corrective orders.193
For example, the defendant in Dotterweich received a penalty of $500
and probation for a period of sixty days.194 In Park, it was even less:
189. United States v. Morton-Norwich Prods., Inc., 461 F. Supp. 760, 763 (N.D.N.Y.
1978) (citations omitted).
190. See supra text accompanying notes 153-58.
191. See Mackenzie Weinger, Health Fraud Busts Rise Sharply, POLITICO (Aug. 30,
2011), http://www.politico.com/news/stories/0811/62306.html ("Federal prosecutions of
health care fraud have skyrocketed and are set to rise 85 percent in 2011 over last year
because of the Obama administration's stepped up emphasis on enforcement.").
192. See Jennifer Bragg, John Bentivoglio & Andrew Collins, Onus of Responsibility:
The Changing Responsible Corporate Officer Doctrine, 65 FooD & DRUG L.J. 525, 528-33
(2010) (detailing the confusion over the mens rea requirement of the RCO doctrine).
193. See supra Parts I.A-B.
194. United States v. Buffalo Pharm. Co., 131 F.2d 500, 501 (2d Cir. 1942), rev'd, 320
U.S. 277 (1943). Calculating in today's dollar value, this amount would only come to
approximately $6,500. See Bragg, Bentivoglio & Collins, supra note 192, at 533.
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$250 in fines and no probation.195 While those types of penalties are
still available to authorities today (albeit at much higher monetary
levels)," the threat of multi-year exclusions looms over misdemeanor
violations in ways that were not envisioned when the doctrine was
originally blessed by the Supreme Court in the mid-1970s. As recent
examples demonstrate, guilty pleas can generate millions in
enforcement fees, jail time, and industry exclusion.197
The fact that a penalty of such disruption is available in
connection with strict liability is difficult to resolve with traditional
views of strict criminal liability. In reviewing the nature of strict
liability in a 1952 opinion, the Supreme Court noted that such a
standard has been found appropriate in scenarios where penalties or
sanctions "are relatively small, and conviction does no grave damage
to an offender's reputation."19 s This view is wholly inconsistent with
the recent linkage of Park's strict liability standard and the modern
version of the exclusion penalty. It is not difficult to imagine that, if
the Dotterweich or Park cases had come before the Court after the
exclusion penalty was in effect, the Court's views on the nature of
strict liability would have led to a different outcome.
The problem is that the use of the Park doctrine's immense
extension of liability will overshoot its intended purpose in an era of
new hyper-regulation. It is a problem of imbalance and misplaced
intent. Both concerns have now begun to play out in the federal
courts. In the past three years, the FDA, HHS OIG, and DOJ have
brought a handful of cases that have appeared to function as warnings
to other medium and large pharmaceutical and health care
corporations.
B. United States v. Purdue Frederick Co. and Friedman v.
Sebelius-Standard of Conduct
Comparing recent cases, such as United States v. Purdue
Frederick Co.19 and its offspring appeal Friedman v. Sebelius,2" helps
195. See United States v. Park, 499 F.2d 839, 840 (4th Cir. 1974), rev'd, 421 U.S. 658
(1975) ("The jury found Park guilty on all counts and he was fined a total of $250.").
196. See 18 U.S.C. § 3571 (2006) (laying out the minimum monetary recoveries, jail
sentences, and exclusion options available for FDCA violations and health care fraud); 21
U.S.C. § 333(a) (2006).
197. See supra notes 112-15 and infra notes 198-201, 212, and accompanying text
(presenting the outcomes of three recent Park doctrine cases).
198. Morrissette v. United States, 342 U.S. 246, 256 (1952) (discussing the general
temper of strict liability and its use in the American criminal justice system).
199. 495 F. Supp. 2d 569 (W.D. Va. 2007).
200. 686 F.3d 813 (D.C. Cir. 2012).
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illustrate the doctrinal changes from the original cases covered earlier
in this Comment.201 This pair of cases has garnered a fair amount of
industry and media attention because HHS, in its original
administrative order, decided to exclude the three executive
defendants from the health care industry for a period of twenty
years. 20 The sheer length of the individual exclusions roused industry
observers, and people outside of the health care field began paying
attention. As previously discussed,2 03 in 2007, the government brought
a corporate criminal action against the Purdue Frederick Co.
("Purdue"), charging it with misbranding the drug OxyContin with an
intent to defraud or mislead.20 OxyContin is a pain medication that is
often used to treat mild to severe pain after medical procedures. The
government also charged three of Purdue's executives for the
misbranding as responsible corporate officers." Armed with
evidence that Purdue had claimed in its marketing and sales practices
that OxyContin was less addictive (and therefore safer) than other
brands of oxycodone (the primary ingredient in OxyContin), the
government received a guilty plea both from the corporation and
from the three executives. 206
The first notable difference between the primary Purdue action
and the pattern of cases established under the original Park doctrine
is the conceded lack of knowledge on behalf of the executive
defendants. As established in the pattern of earlier cases, Park
prosecutions were only brought where there was enough evidence to
fulfill a negligence standard (instead of the easier strict liability
standard that was formally expressed in the law). 207 In Purdue,
however, this standard changed. Since the main issue in this case was
simply whether the court could accept the plea agreements as fair and
equitable,2 08 direct attention was called to the terms of those
201. See supra Part I.A-B.
202. See Friedman v. Sebelius, 755 F. Supp. 2d 98 (D.D.C. 2010), rev'd, 686 F.3d 813
(D.C. Cir. 2012).
203. See supra text accompanying notes 106-20.
204. See 21 U.S.C. §§ 331(a), 333(a)(2) (2006).
205. See United States v. Purdue Frederick Co., 495 F. Supp. 2d 569, 571 (W.D. Va
2007). The three executives were Michael Friedman, the former Purdue CEO; Howard
Udell, the executive Vice President and Chief Legal Officer, and Paul Goldenheim, the
former chief scientific officer. See id at 570 n.2.
206. Id.
207. See supra Part II.A.
208. In sentencing, federal courts are not bound by the terms of a plea agreement.
See FED. R. CRIM. P. 11(c)(1)(C).
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agreements as they related to the underlying facts of the case.209
Notably, the district court for West Virginia accepted the executive
defendants' plea agreements, all of which expressly stated that none
of them ever had any personal knowledge of the underlying
misconduct, but would nevertheless accept guilt based solely on their
position as a responsible corporate officer.2"o
After the court in Purdue accepted the plea agreements of the
individual defendants,2 11 HHS regulators, conviction in hand, used the
statutory authorities under 42 U.S.C. § 1320a-7(b)(1) and (3) to
enforce a permissive exclusion on each individual executive for a
period of twenty years. 2 12 Section 1320a-7(b)(1) predicates exclusion
on the conviction of a misdemeanor offense "relating to fraud . .. in
connection with the delivery of a health care item or service." 2 13 After
multiple administrative hearings (and one failed court visit)2 14 in
which they argued that this penalty was too severe given the amount
of money and probation time the defendants had accepted as part of
their plea agreements ($34 million amongst all three), the executives
had their exclusion terms reduced, but only down to twelve years.2 15
They then filed suit against HHS. 216 After the district court for West
Virginia affirmed the exclusion, the D.C. district court's opinion
addressed both the standard of conduct required for a conviction and
the reasonableness of the exclusion decision.217
On the legality of the exclusion, the district court simply
reiterated the statutory law on the ability of the Secretary of HHS to
apply the penalty, noting that, despite defendants' lack of knowledge,
they were guilty because of their status as responsible corporate
officers and therefore legally subject to the decision.' Like the
Secretary's original decision, the district court did not elaborate on
209. See generally Agreed Statement of Facts, Purdue Frederick Co., 495 F. Supp. 2d
569 (No. 07CR00029), 2007 WL 1423894 (outlining the facts that were agreed upon by
both parties).
210. See Purdue, 495 F. Supp. at 571.
211. The three individual defendants, in addition to the $100,000 required HHS fine,
agreed to pay a total of $34.5 million to the Virginia Medicaid Fraud Division's Income
Fund. See id. at 573. Defendant Friedman agreed to pay $19 million, and defendants Udell
and Goldenheim agreed to pay $8 million and $7.5 million, respectively. Id. at n.3.
212. See Friedman v. Sebelius, 755 F. Supp. 2d 98 (D.D.C. 2010), rev'd, 686 F.3d 813
(D.C. Cir. 2012).
213. 42 U.S.C. § 1320a-7(b)(1)(A)(ii) (2006).
214. Friedman, 755 F. Supp. 2d at 103 (dismissing on grounds of failure to exhaust
administrative remedies).
215. See id. at 104.
216. See id.
217. See id. at 105-06.
218. Id. at 113.
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what the term "in relation to" meant under the convicting statute, 42
U.S.C. § 1320a-7(b)(1)(A)(ii). This failure to do so left a gap in the
legal analysis that unfortunately was unaddressed by the circuit court
on appeal as well. In spite of this problem, there is one notable line in
this opinion that does a good job demonstrating the drift between the
original use of the Park doctrine and its more recent installment.
Federal District Judge Ellen Segal Huvelle wrote: "Moreover,
plaintiffs can hardly be heard to argue now, over three years after
pleading guilty to the criminal charges against them, that they did not
engage in any 'wrongful' or 'culpable' conduct."219 Judge Huvelle's
skepticism here misses the point and exposes the fundamental shift
that has taken place. Whereas the district court for West Virginia
(and FDA) were fully accepting of the defendants' claims that they
had no personal knowledge of the underlying misconduct,220 Judge
Huvelle dismisses those claims altogether, as if the passage of time
has had some effect on the validity of their statements during an
earlier stage of the litigation. She notes that "[i]t strains credulity to
argue that ... they. . . 'were convicted based solely on their status as
senior executives, without any culpability or wrongful action on their
part at all.' "221 Of course, this is precisely what the accepted terms of
the plea agreement expressed. In no way did the executives' position
at Purdue bear on their personal culpability as to the off-label
marketing violations. Judge Huvelle's dismissal of this fact is plainly
incorrect.
What's more, it is wholly unnecessary for Huvelle to make such a
claim to begin with if the standard of the Park doctrine is truly one of
strict liability, since strict liability offenses, by definition, carry no
requirement of moral wrongfulness or culpability. This view is also
consistent with the FDA's guidance on Park prosecutions, which
stresses that a responsible corporate official can be held liable
"without proof that the corporate official acted with intent or even
negligence. "222 If intent or moral wrongfulness play no role in a strict
liability offense, and the mutually accepted plea agreement expressly
released the individuals from wrong doing, it seems highly
disingenuous for Judge Huevelle to admonish the defendants for their
role in the violation.
219. Id. at 111.
220. See supra text accompanying note 211.
221. See Friedman, 755 F. Supp. 2d at 111 (quoting Memorandum of Points and
Authorities in Support of Plaintiffs Motion for Summary Judgment at 3, Friedman, 755 F.
Supp. 2d 98 (No. 09-2028 (ESH)).
222. See FOOD & DRUG ADMIN., supra note 125, § 6-5-3.
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Perhaps most alarming is the district court's wielding of the
exclusion authority while demonstrating a lack of understanding
about the U.S. health care industry. Health care in the United States
has become highly government-dependent, with federally funded
programs providing nearly one-third of national medical
expenditures.2 3 The importance of federal funding in the
pharmaceutical industry is even more pronounced. Between 1998 and
2010, the growth in federal funding for basic drug and disease
research was nearly equal to that provided by the private sector.22 4 In
both the health care and pharmaceutical sectors, identifying a
company that receives absolutely zero federal funds, "directly or
indirectly,"22 5 is nearly impossible. Yet, despite this reality, Judge
Huvelle decided that the "consequences of exclusion are not nearly as
dire as plaintiffs contend, as plaintiffs remain free to seek private
employment at a company that does not rely on federal or state
funds."226
In the D.C. Circuit's review of Judge Huevelle's decision, it
approved the combination of the Park conviction and subsequent
exclusion penalty, but reversed the district court judge's affirmation
of the length of exclusion, finding that the twelve-year duration was
arbitrary and capricious.2 27 Because HHS had not cited any past
instances where it had issued such a lengthy exclusion (the longest to
date had been four years),228 the circuit court held that the decision
could not be supported by past precedent.2 29 While this technical
reversal may have helped reduce the term of the exclusion for the
executive defendants, it implicitly approved HHS's use of the
exclusion penalty predicated on a Park doctrine conviction. The
court, like the Secretary and district court, approved of drawing a
connection between the executives and the necessary fraud via the
words "relating to" in that their conviction for the corporation's off-
223. See CTRS. FOR MEDICARE & MEDICAID SERVS.,supra note 136, at 3.
224. See CONGRESSIONAL BUDGET OFFICE, PHARMACEUTICAL R&D AND THE
EVOLVING MARKET FOR PRESCRIFTION DRUGS 3 (2009), available at http://www.
cbo.gov/ftpdocs/106xx/doclO681/DrugR&D.shtml#1044432.
225. OIG Special Advisory Bulletin on the Effect of Exclusion from Participation in
Federal Health Care Programs, 64 Fed. Reg. 52791,52793 (Sept. 30, 1999).
226. See Friedman, 755 F. Supp. 2d at 98.
227. See Friedman v. Sebelius, 686 F.3d 813, 828 (D.C. Cir. 2012).
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label marketing was a misdemeanor "relating to" fraud under
§ 1320a-7(b).230
However, in his dissent, Judge Williams confronted this glaring
lack of definition for the words "relating to": "Very troublingly,
without such an effort at seeking the legal meaning of the disputed
clause, we have a reading by the Secretary that offers none of the
'precision and guidance [that] are necessary so that those enforcing
the law do not act in an arbitrary or discriminatory way.' "231 Judge
Williams's comment calls on HHS to develop perceivable regulatory
thresholds before enforcing such a disruptive administrative penalty.
Indeed, he is channeling the Supreme Court's own warning from
Dotterweich that reminded government regulators that, when dealing
with such a potent legal doctrine, "the good sense of
prosecutors. . . must be trusted.""
C. New Regulations-Public Protection or Profit?
While the development of the Park doctrine's standard of
conduct in Purdue and Friedman is at play in other recent
situations, another change from the original Park/Dotterweich
framework has arrived in the regulations and laws that surround it.
As a general public welfare measure, the aim of the statutes that
define the Park doctrine are glossed, at least in name, with protecting
the health and safety of the public: "The purpose of exclusion is to
protect the Medicare, Medicaid, and all Federal health care programs
from fraud and abuse, and to protect the beneficiaries of those
programs from incompetent practitioners and from inappropriate or
inadequate care."234 However, evidence on how the government is
using the exclusion authority demonstrates that other motivations are
afoot.
As stated earlier, general health care fraud actions are increasing
at an alarming rate.2 35 With eighty-five percent more claims year-
230. Id. at 824. The Court agreed with the Secretary using the term "nexus" between
the executive's convictions and the statutory basis for their exclusion. See id.
231. Id. at 831 (Williams, J., dissenting in part, concurring in part, and concurring in the
judgment) (quoting FCC v. Fox Television Stations, 132 S. Ct. 2307, 2317 (2012)).
232. United States v. Dotterweich, 320 U.S. 277, 285 (1943). Indeed, these words were
written before the exclusion penalty existed.
233. See, e.g., United States ex. rel. Gobble v. Forest Labs., 729 F. Supp. 2d 446 (D.
Mass. 2010); see also Vanessa O'Connell & Michael Rothfield, U.S. Targets Drug Execs,
WALL S. J., Sept. 13, 2011, at B.
234. Anderson v. Thompson, 311 F. Supp. 2d 1121, 1124 (2004) (citing S. REP.
No. 100-109, at 2 (1987), as reprinted in 1987 U.S.C.C.A.N. 682,682).
235. See Weinger, supra note 191.
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over-year between 2010 and 2011,3 the message to the industry is
clear: enforcement is on the rise. What is also clear is the
government's renewed appetite for collecting fees and settlement
payments. In 2011 alone, the government collected over $1.2 billion in
payments from just five pharmaceutical settlements." The amount of
money to be made in this area of regulation is enormous.
While enforcement of health care and FDCA provisions is
consistent with increased protection of the public health (and the
government's programs), a legislative move in 2010 amending the
Patient Protection and Affordable Care Act ("PPACA") revealed
another side of the government's policy motivations. In the original
version of PPACA that was signed into law on March 23, 2010,
section 6502 increased the severity of the exclusion penalty so that
any guilty plea by an individual or subsidiary company would
necessarily also result in the exclusion of the entire parent enterprise
from all Medicaid payments simply by virtue of association. Under
a purely protectionist-minded regulatory state, this makes perfect
sense: The increased severity of the exclusion authority in section
6502 was logically connected with a desire for higher deterrence.
However, after HHS attorneys quickly realized that this new
requirement was interfering with their ability to settle cases quickly,
they asked Congress to get rid of section 6502 altogether.2 39 On
December 15, 2010, less than one year after PPACA passed, H.R.
4994 was signed into law as the Medicare and Medicaid Extenders
Act of 2010.240 Section 205(a) of the new bill repealed the strict terms
of PPACA section 6502.241 By default, this move placed HHS in the
original situation with its less stringent, but more flexible exclusion
236. Id. ("Federal prosecutions of health care fraud have skyrocketed and are set to
rise 85 percent in 2011 over last year because of the Obama administration's stepped up
emphasis on enforcement.").
237. HOPE S. FOSTER ET AL., MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC,
2011-THE YEAR IN REVIEW: TRENDS IN HEALTH CARE ENFORCEMENT 4 (Jan. 31,
2012), http://www.mintz.com/newsletter/2012/Advisories/1618-0112-NAT-HCED/1618-
0112-NAT-HCEDjindex.pdf.
238. See Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 6502, 124
Stat. 119, 776 (2010) (codified as amended at 42 U.S.C. § 1396a(a)(78) (2010)), repealed by
Medicare and Medicaid Extenders Act of 2010, Pub. L. No. 111-309, § 205(a), 124 Stat.
3285,3290 (codified at 42 U.S.C. § 1396a(a) (2012)).
239. See Alan M. Kirschenbaum, Notorious Affiliate Exclusion Provision of PPACA
Repealed, FDA L. BLOG (Dec. 21, 2010, 8:16 AM), http://www.fdalawblog.net/
fda law bog-hyman-phelps/2010/12/notorious-affiliate-exclusion-provision-of-ppaca-
repealed.htmi.
240. See Medicare and Medicaid Extenders Act of 2010 § 205(a), 124 Stat. at 2390.
241. See id.
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maneuvers secured.242 This quick shift represents the fact that, in
some material way, the motivation behind using the Park doctrine to
generate more exclusion scenarios for pharmaceutical and health care
corporations is driven not by the increased protection of the public,
but by a desire to maintain an increasing flow of settlement money
into government collection accounts. If public welfare protection was
truly the full motivation for the exclusion actions (as the statute
claims), the more severe penalty that was briefly available would have
been the most logical choice.
D. Changing the Corporation's and Individual's Plea Calculus
Taken all together, one would assume that the above changes
from the original Park doctrine would, if the pharmaceutical industry
functions like others, result in an increased amount of settlements.
24 3
To a large extent, this view is correct. Rising litigation costs and
conventional wisdom suggest that companies and individuals both, on
average, would rather settle claims than risk higher penalties in the
event of an adverse jury ruling. However, in dealing with Park
prosecutions, the three-way dynamic between the corporation, the
corporation's implicated responsible officer, and the government
prosecutor becomes much more complex. The main difference is that,
in two-way negotiations, opposing parties will typically interact with
each other to reach a mutually agreeable (but not necessarily
desirous) set of terms, while three-way negotiations wherein none of
the parties' interests are congruent with one another will result in a
different and more complex set of considerations.2 " A corporation's
desire to strike a quick plea bargain with the government (as lethargy
usually decreases an opposing party's willingness to compromise) is
countered by the personal interests of a responsible officer within the
242. See Kirschenbaum, supra note 239 ("The provision would have severely
constrained the Department of Justice's ability to negotiate settlements that would impose
appropriate penalties on drug and device manufacturer without harming Medicaid
beneficiaries.").
243. See John H. Langbein, On the Myth of Written Constitutions: The Disappearance
of Criminal Jury Trial, 15 HARV. J.L. & PUB. POL'Y 119, 121 (1992) (noting that plea
bargaining "has become the ordinary dispositive procedure of American criminal
justice").
244. For an excellent discussion on the increased complexity in hostile three-party
negotiations scenarios, see generally D. Marc Kilgour & Steven J. Brams, The Truel, 70
MATHEMATICS MAG. 315, 315 (discussing the various ways in which three-party games
differ from two-party games: "In duels, the interest of game theorists lies in the nature and
timing of each player's actions against its opponent. In truels, another strategic
consideration comes into play-namely, that a player must also decide which, if either,
opponent to fire at, bringing in the target aspect of a confrontation").
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corporation since, once the government has the corporation's guilty
plea with an agreed statement of facts in hand, pegging those events
to the individual responsible corporate officer position would not be
difficult in a strict liability framework. In other words, if the
government can secure, via the corporation's admission, that a
violation occurred, all the government prosecutor needs to do is
establish that some corporate officer stood in a responsible relation to
the activity that caused the violation.
Yet, this is only one version of a three-party hostile negotiation.
This initial three-party scenario presumes that the government values
the plea bargains (or convictions) of the corporation and the
individual equally.245 If we introduce an element of preference on
behalf of the government, the relationships between the three parties
becomes even more complex. This second modified version of the
settlement negotiation is more consistent with actual Park doctrine
scenarios since the government may often prefer to secure one party's
guilty plea over another. In highly publicized cases, for example,
"convictions of individuals can be more impactful than convictions of
corporations."' It is not difficult to imagine a situation where the
government, in dealing with the corporation directly, might take
measures to incentivize the corporation to agree to a precise version
of facts in the plea bargain in order to make it easier to define the
individual as a responsible officer. This might occur in high-profile
cases where putting a face to a crime is popularly desirable. If, on the
other hand, the government is more interested in getting at a
corporation's vast resources, it would be in the government's favor to
incentivize the individual to disclose certain pieces of information to
make that recovery easier.24 7 In either scenario, the government
stands to benefit by playing the corporate defendant and its
responsible corporate officer off one another.
245. See Bragg, Bentivoglio & Collins, supra note 192, at 536.
246. Id.
247. A good example of this scenario possibly occurred in 2005 when "Eli Lilly pled
guilty to one misdemeanor misbranding count and paid $36 million to settle allegations
that the company marketed its drug Evista for off-label uses." BRENT J. GURNEY ET AL.,
WILMER CUTLER PICKERING HALE AND DORR LLP, THE CRIME OF DOING NOTHING:
STRICT LIABILITY FOR CORPORATE OFFICERS UNDER THE FDCA, at F-18 (2007),
http://www.wilmerhale.com/files/Publicationf7blcO866-a547-48c7-86d0-
04d0449cO3d7/Presentation/PublicationAttachment/c5eda281-2dae-454-a~f8-
13b817f25b52The_Crime_ofDoingNothing.pdf. The off-label marketing plan was
comprehensive and included "sales representative training materials, a press release, a
consumer magazine ad, and unsolicited letters to physicians discussing Evista's use in
breast cancer prevention." Id. Yet, despite such ripe circumstances for a Park prosecution
against Eli Lilly's executives, no such action was brought. See id.
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Battles between a corporation and its management often throw a
company into havoc and damage shareholder value. For example, the
aftermath of one of these settlement scenarios is currently being
played out in bitter lawsuits between a pharmaceutical company, KV
Pharma, and its ex-CEO, who voluntarily stepped down after
receiving a twenty-year exclusion penalty from the FDA.2 48 The
competing suits each claim that the other party was responsible for
the non-recall of problematic morphine tablets in 2008.249 The
disruption was large. Not only will the ex-CEO no longer be able to
participate in any health care or pharmaceutical company that
receives any federal funding for the twenty year period, but the
company itself, in an attempt to recover from the fines levied,
"recalled its drugs, laid off three-quarters of its employees and halted
its manufacturing operations for almost two years." 20 If settlement is
typically the desired outcome," pharmaceutical firms and their
executives must be wary of their relative bargaining positions to one
another and to the government in order to avoid situations analogous
to the KV-Pharma situation.2 52
IV. POLICY PROBLEMS AND PROPOSALS
A. Policy Concerns
The ultimate effect of this general move toward increased
utilization of a strict liability enforcement tool is the transformation
of the threat of personal liability into a formal mechanism of industry
regulation. Aside from the implications that such a shift poses to
traditional notions of criminal liability, this overarching policy
decision has significant practical implications as well.
First, it may create artificial and inefficient management
structures in large corporations in order to distance upper executives
from potential misconduct at a lower level. Additionally, "executives
might go overboard in designing and implementing expensive
248. See George Miller, KV Pharma, Ex-CEO Battle of Recall Responsibility, FIERCE




250. Andrew McConaghie, Crisis in the Boardroom: 2011's Most Dramatic Departures,
INPHARM (Jan. 11, 2012, 10:51 AM), http://www.inpharm.com/news/170776/crisis-
boardroom-2011-s-most-dramatic-departures.
251. Erik Luna, Traces of a Libertarian Theory of Punishment, 91 MARQ. L. REv. 263,
263, 281 (2007) (noting that ninety percent of criminal cases are now concluded with a plea
bargain).
252. See notes 112-13 and accompanying text.
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procedures to reduce the probability of corporate crimes." 2 53 These
tactics may often result in layers of executive middle-management,
which in turn hurt a corporation's flexibility. 254 The trend toward
setting up corporate compliance offices, a practice encouraged by
liability-minded lawyers, may be motivated by the increased risks of
executive liability. 255 Indeed, many white collar defense lawyers
suggest increasing internal controls and reporting capabilities as a
direct response to the increase in RCO liability." When decisions to
add costly layers of management are based on the hopes that such
layers will shield certain individuals at the top of the management
structure from responsible corporate officer liability, there is
increased potential for shareholders to suffer the consequences since
the cost and rigidity of these layers may reduce the overall value of
the corporation.
Second, the Park doctrine's growing application of strict and
vicarious liability to individual officers within the health care and
pharmaceutical industries should act as a warning to executives and
corporate counsel in other industries. The supposed rationale for this
flavor of liability in health-related sectors is to protect the public
welfare and deter government fraud, but extending it to other
industries that handle areas of significant public importance (i.e.,
banking) does not seem like a large leap. It is surprising that Park
liability is not enforced against large banks, given the fact that large
financial institutions sit in an arguably "responsible relation" to the
fiscal demise of many Americans through evidence of depleted
retirement funds and illegal home loan approvals.25 7 Indeed, last year
law firms began publishing client alerts detailing the increased
253. See Corporate Crime: Regulating Corporate Behavior Through Criminal Sanctions,
supra note 150, at 1272.
254. See HERBERT A. SIMON, ADMINISTRATIVE BEHAVIOR: A STUDY OF DECISION-
MAKING PROCESSES IN ADMINISTRATIVE ORGANIZATION 142-45 (3d ed. 1976).
255. See Roderick L. Thomas & Mark B. Sweet, Can You Survive a Fraud
Investigation? Part 1: A Practical Guide to Preparing for Government Investigations,
METROPOLITAN CORP. COUNS. (Feb. 17, 2012, 9:05 AM), http://www.
metrocorpcounsel.com/articles/17914/can-you-survive-fraud-investigation-part-1-practical-
guide-preparing-government-inves.
256. See, e.g., id.
257. See Peter J. Henning, Is That it for Financial Crisis Cases?, N.Y. TIMES
DEALBOOK (Aug. 13, 2012, 11:22 AM), http://dealbook.nytimes.com/2012/08/13/is-that-it-
for-financial-crisis-cases/ ("New laws would not make it any more likely that senior
executives could be pursued unless they included liability as a 'responsible corporate
officer' for the conduct of underlings without having to prove an executive's knowledge or
recklessness." (emphasis added)).
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attention to government enforcement of financial fraud. Park
liability would fit easily into such a regulatory effort.
A third concern surrounding the future of the Park doctrine is its
application to off-label marketing. Off-label marketing occurs when a
pharmaceutical company sales representative markets drugs to
physicians for uses other than those that have been approved by the
FDA. This practice is an actionable health care offense under 21
U.S.C. § 331 and therefore may set the grounds for the criminal
conviction of a responsible corporate officer under Park strict
personal liability.2 59 The validity of criminalizing off-label promotion
can be debated from a policy perspective, but the FDA has
consistently held that marketing any non-approved use, no matter its
proven medicinal purposes, is illegal until the use is officially
sanctioned by the Agency. 260
However, companies still occasionally engage in the practice
when they have hard data on hand that their unapproved use actually
works to treat a certain condition, and engaging in this kind of
truthful off-label promotion has been met with some legal success. 261
In the recent decision in Sorrell v. IMS Health, Inc.,262 the Supreme
Court struck down a Vermont law prohibiting drug companies' use of
their own data about the prescription trends of individual doctors and
pharmacists. 63 Such data can potentially be used to target product-





259. See 21 U.S.C. § 311(k) (2006).
260. See Coleen Klasmeier & Martin H. Redish, Off-Label Prescription Advertising, the
FDA and the First Amendment: A Study in the Values of Commercial Speech Protection, 37
AM. J.L. & MED. 315, 318 (2011) ("[Tlhe FDA has categorically banned manufacturers of
drugs and devices from promoting their use for unapproved purposes to the medical
profession."). But see United States v. Caronia, 703 F.3d 149, 168-69 (2d Cir. 2012)
(holding that a promotion of a prescription drug for a non-approved use is permissible so
long as the promotion is truthful).
261. This is because a doctor may still prescribe a drug for a non-approved use without
any interference from the FDA and because the FDA recognizes the innovative benefits
that can flow from off-label prescriptions. See "Off-Label" and Investigational Use Of
Marketed Drugs, Biologics, and Medical Devices-Information Sheet, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/Regulatorylnformation/Guidances/ucml26
486 .htm (last
updated Aug. 10, 2011) ("Good medical practice and the best interests of the patient
require that physicians use legally available drugs, biologics and devices according to their
best knowledge and judgment."); see also Klasmeier & Redish, supra note 260, at 318
("[MJanufacturers are in a unique position to provide valuable information about off-label
uses to the medical profession.").
262. 131 S. Ct. 2653 (2011).
263. Id. at 2659.
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marketing efforts to specific doctors and medical practices. Going
further, the Second Circuit, relying on the Sorrell decision, also
recently reversed a doctor's conviction for off-label marketing based
on the fact that, despite promoting a drug for an off-label use, the
promotion itself was truthful and therefore considered protected
speech under the First Amendment.2' Without going too far into
First Amendment analysis, the Supreme Court's and Second Circuit's
rulings set the stage for a reconsideration of off-label marketing
policy. While this is the general trend in Park doctrine application,
these decisions represent at least one major area of pharmaceutical
regulation in which the doctrine may begin to decline.
B. Policy Alternatives
We no longer live in an economy where pharmaceutical
companies and health care corporations can be fully overseen by any
one individual. A cursory glance over the employment numbers of
any major pharmaceutical companies helps demonstrate the scope of
these mammoth organizations. For example, Johnson & Johnson
employs 114,000 people, maintains locations in sixty countries, and
sells its products in nearly every country in the world.265 It also has
1,549 executives. 2" The notion that a single individual can stand in
responsible relation to every action of this humongous population is
unrealistic. In this sense, the industry has simply outgrown the key
rationale behind the Park doctrine that a CEO can be accountable for
everything that occurs at his or her pharmaceutical company. By
using a strict liability standard for FDCA and health care fraud
offenses, executives are incentivized to actually reduce their oversight
since such a management approach reduces their responsibility for
any underlying violation. This could include creating intermediate
semi-executive bodies or avoiding making key management decisions.
Placing liability on the actual actors culpable for any violation, as
opposed to on the company's executives, would have a positive
operational effect in two ways. First, it would help reverse the
incentive for executives to distance themselves from potentially
264. See Caronia, 703 F.3d at 166 ("As off-label drug use itself is not prohibited, it does
not follow that prohibiting the truthful promotion of off-label drug usage by a particular
class of speakers would directly further the government's goals of preserving the efficacy
and integrity of the FDA's drug approval process and reducing patient exposure to unsafe
and ineffective drugs.").
265. Johnson & Johnson, Annual Report (Form 10-K), at 1-2 (Feb. 25,2011).
266. See Johnson & Johnson Company Information, HOOVERs, http://www.
hoovers.com/company/Johnson-Johnson/rfxtci-1.html (last visited Nov. 11, 2012).
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violative activities. Second, it would help breed more individual
responsibility further down the ranks of a corporation's employment
structure. Furthermore, such a regulatory move would be consistent
with viable principles of business organization that have created
significant value for shareholders. The theory is that, if liability
extends further down the corporate ladder, those employees who also
would become subject to a legal penalty for their misconduct will
operate with increased diligence. This model of decentralized
authority has found success in the real world. AES, now one of the
world's largest energy providers, has operated on a decentralized
structure from its beginning in the early 1980s. 267 At its height in 2000,
AES employed more than 10,000 people in nineteen countries, yet
kept less than thirty employees total at its headquarters 2 6 Two
researchers explained that at AES "[b]usiness development is the
responsibility of almost everyone ... including relatively junior
people." 269 Roger Sant, long-time CEO of AES, commented that a
driving philosophy at a company had always been that "[t]he
organization has assumed that their people are good, that they really
want to make a difference; that you don't need to control them; that
you can depend on them."2 70
Another policy alternative suggested by food and drug law
attorney Ariel Glasner is to simply adjust the standard of conduct
under which Park doctrine actions may be brought from a strict
liability standard to a gross negligence standard.271 This change would
not require a complete overhaul of existing statutory language or
administrative practice, and would still require a corporate officer to
be diligent in his perception and prevention of violations. Such a
change would also help resolve the dissonance between the strict
liability standard expressed in the letter of the law and the apparent
negligence standard that has traditionally accompanied Park
prosecutions.2 72 This change would also be more consistent with the
267. NIKOLAI ROGOVSKY & EMILY SIMS, CORPORATE SUCCESS THROUGH PEOPLE:
MAKING INTERNATIONAL LABOUR STANDARDS WORK FOR You 58 (2002).
268. Id.
269. Id.
270. Id. at 59.
271. Ariel Glasner, Are Misdemeanor Prosecutions Under the Park Doctrine an
Effective Mechanism for Deterring Violations of the Federal Food, Drug, and Cosmetic




272. See supra Part III for a discussion of the historical variance between these two
standards.
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standards expressed in the Park case, as the Court never mentioned
the use of strict liability.m' Most importantly, using a negligence
standard would help define for companies who qualifies as a
responsible corporate officer. The current FDA guidelines on the
definition expressly state that defining who is and is not a responsible
corporate officer is futile.27 4 While no black-letter definition needs to
be set out, companies would be better able to understand what
positions qualify for such a definition based on a negligence
standard's insistence on what any one particularly responsible
corporate officer should have known or should have done. With the
current strict liability standard, corporate counsel can be left guessing
at precisely which acts or omissions of a particular responsible
corporate officer will result in a Park prosecution. The negligence
standard would help bring better-defined standards to this situation,
which should result in more predictability about what exposes
corporate officers to liability.
CONCLUSION
The dynamics of modern Park doctrine cases represent a
fundamental shift away from the original function and intent of the
doctrine as it was understood at its founding and development in the
1970s. Not only have the mechanics of the doctrine been altered, but
there is evidence to suggest that it serves an entirely different purpose
from its original form. While there are laudable goals at hand in its
use, the overall structure, particularly in conjunction with the use of
the exclusion authority, depicts a regulatory movement that is more
concerned with the ends than with the means. Despite the
prophylactic effects and the doctrine's sheer power that it holds over
the pharmaceutical and health care industries, it has come at the
expense of distorting the delicate and controversial concept of strict
liability and turning it into an oversized tool of legal leverage.
ANDREW C. BAIRD4
273. See United States v. Park, 421 U.S. 658, 670-71 (1975).
274. See FOOD & DRUG ADMIN., supra note 125, § 6-5-3.
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